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ABSTRACT 
Reactive oxygen species (ROS) are produced as a consequence of cellular metabolism and 
can also be produced by the cell in response to growth factor/growth factor receptor 
stimulation to function as second messengers in major signalling pathways. Recently, 
increasing evidence has revealed that the ROS, H2O2 is an important second messenger in 
cellular signal transduction, because of its high diffusion and ability to selectively target 
reactive cysteine residues in proteins. Currently, H2O2-mediated signalling has been 
implicated in several fundamental physiological processes such as cell proliferation, 
differentiation, migration and apoptosis. EGF/EGFR is one of the most mutated GF/GFR 
associations in cancer thanks to its role in tumorigenesis. The binding of EGF to EGFR 
induces downstream events leading to intracellular production of H2O2 for signalling. Cancer 
cells characteristically exhibit increased ROS levels compared to normal counterparts that 
gives them a proliferative advantage and promotes cancer progression. To balance the 
advantage of low ROS levels (nanomolar concentration for proliferative signalling pathways) 
against its damaging effect (as a specific oxidant at high concentrations), cancer cells induce 
the cellular antioxidant response. Our laboratory identified a novel redox regulatory protein, 
annexin A2 (ANXA2) and showed that its antioxidant function plays a crucial role in 
supporting tumour growth and chemoresistance. As a logical follow up to this research we 
investigated the role played by ANXA2 in oncogenic signalling pathways induced by EGF. 
Here, the activation of signalling pathways in pre-established MDA MB 231 breast cancer 
cell lines with knockdown for ANXA2 and respective control cells was investigated by 
western blotting upon treatment of these cells with 50 ng/ml of EGF at different time points. 
Biotinylated Iodoacetamide (BIAM) assays were done to assess the oxidation of reactive Cys 
residues in redox sensitive proteins upon treatment with EGF. Intracellular ROS levels and 
cell proliferation were also analysed in ANXA2 depleted versus control cancer cells upon 
treatment with EGF. Our results show that ANXA2 depletion in MDA MB 231 cancer cells 
leads to enhanced activation of the pro-survival and pro-proliferative PI3K/Akt signalling 
pathway, enhanced ROS production and increased proliferation rate upon EGF treatment 
compared to control cells. EGF treatment also led to oxidation/inhibition of the main 
regulator of the PI3K/Akt pathway, PTEN. Interestingly, we observed upregulation of PRDX 
II (a redox regulatory protein) in ANXA2 depleted MDA MB 231 cells. Taken together, our 
results demonstrate that ANXA2 plays a redox regulatory role in EGF induced ROS-
mediated PI3K/Akt signalling and that ANXA2 knockdown cells might be upregulating 
PRDX II to compensate for the loss of the ANXA2 redox regulatory protein.  
Key words: Annexin A2 (ANXA2), reactive oxygen species (ROS), epidermal growth factor 
(EGF), phosphoinositide 3-kinase (PI3K) 
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1. INTRODUCTION 
1.1. Cancer 
As defined by the World Health Organization (WHO), cancer is the uncontrolled growth and 
invasive spread of cells which can ubiquitously affect the body. Several decades of cancer 
research have led to the conclusion that cancer is not a single disease since it can occur almost 
anywhere in the human body. Cancer types are grouped into the following categories based 
on their cell of origin: 
- Carcinomas - Cancers that originate from epithelial cells such as the cells that 
constitute the skin or tissues lining internal organs. Carcinomas constitute more than 
80% of all existing cancers. Carcinomas constitute more than 80 % of all existing 
cancers. The subtypes of carcinoma include adenocarcinoma, basal cell carcinoma, 
squamous cell carcinoma and transitional cell carcinoma. 
Adenocarcinomas originate from epithelial cells that produce fluids or mucus 
(glandular tissues). Most cancers of the breast, colon, and prostate fall within this 
category.  
Basal cell carcinomas originate from the lower or basal layer (stratum basale) of the 
epidermis, that is, the outer layer of the skin. 
Squamous cell carcinomas (epidermoid carcinomas) originate from squamous cells, 
which are the epithelial cells that lie just beneath the outer surface of the skin. 
Squamous cells also form the lining of many other organs, including the intestines, 
lungs, stomach, bladder, and kidneys and could be the cells of origin for some 
cancers occurring in these organs. 
Transitional cell carcinomas originate from the transitional epithelium, or urothelium 
(multiple layers of epithelial cells which can expand and/or contract). This tissue is 
present in the linings of the ureters, bladder, renal pelvis, and a few other organs. 
Some cancers of the bladder, ureters, and kidneys fall within this category. 
- Sarcomas - Cancers that originate from mesenchymal cells, including bone, 
cartilage, muscle, fat, blood vessels, or other supportive or connective tissues. 
Osteosarcoma is the most common bone cancer, and the most common types of soft 
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tissue sarcomas include Kaposi’s sarcoma, leiomyosarcoma, malignant fibrous 
histiocytoma, liposarcoma, and dermatofibrosarcoma protuberans. 
- Leukaemia - Cancers that usually originate from the bone marrow and lead to the 
production of large numbers of circulating abnormal blood cells. These cancers do 
not form solid tumours and are mainly constituted of circulating leucocyte progenitor 
cells, usually referred to as leukaemia cells and leukemic blast cells. Leukaemias are 
grouped based on how quickly the disease unfolds (acute or chronic) and on the type 
of blood cell of origin (lymphoblastic or myeloid). The four most common types 
include acute myeloid leukaemia, acute lymphoblastic leukaemia, chronic myeloid 
leukaemia and chronic lymphocytic leukaemia. 
- Lymphomas - blood cell cancers that develop from lymphatic cells (T or B 
lymphocytes). Here, abnormal lymphocyte populations accumulate in lymph nodes, 
lymph vessels, as well as in other organs of the body where they form solid tumours 
(as opposed to leukaemias). The two main types of lymphomas include: 
Hodgkin’s lymphoma – which originates from abnormal lymphocytes called Reed-
Sternberg cells which originate from B cells. 
Non-Hodgkin’s lymphoma – which originates from lymphocytes, can grow quickly 
or slowly and can arise from B or T lymphocytes. 
- Multiple Myeloma (plasma cell myeloma and Kahler disease) - Cancer that 
originates from plasma cells, leading to the formation of abnormal plasma cells 
called myeloma cells which build up in the bone marrow and form tumors in the 
bones all throughout the body. 
- Melanoma - Cancer that originates from the pigment-producing melanocytes in the 
basal layer of the epidermis. Most melanomas form on the skin, but can also form in 
other pigmented tissues, such as the eye (intraocular melanoma). 
- Neuroectodermic cancers - cancers that originate from cells of the central and 
peripheral nervous system. They are named based on the type of cell of origin and the 
site of formation of the primary tumour in the central nervous system and include: 
gliomas, glioblastomas, neuroblastomas, meduloblastomas, astrocytomas and 
retinoblastomas. 
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Normal homeostatic functioning of the human body relies on tightly regulated 
communication and cooperation among cells and tissues. Defects in the aforementioned has 
several consequences, one of which being carcinogenic cellular transformation. Cancer 
results from the concerted mutations of a set of genes that normally control cell growth, 
proliferation, differentiation, DNA repair and apoptosis which are normal innate metabolic 
processes. These mutations give rise to oncogenes with dominant gain of function and tumour 
suppressor genes with recessive loss of function 1. However, the conversion of normal human 
cells into malignant tumour cells is a multistep process occurring through a sequence of 
spontaneous and/or biochemically induced genetic alterations, each leading to different types 
of growth and survival advantages 2. Cancer therefore turns out to be an unfortunate 
consequence of the multicellular mode of life. The physiological manifestations of 
carcinogenic mutations occur through six major alterations which include: independence 
from growth signals, circumvention of growth-inhibitory signals, bypass of apoptosis, 
unlimited replicative ability, induced and sustained angiogenesis, and invasion of tissues and 
metastasis 2. Other recently identified cancer specific alterations include: significant 
reprogramming of energy metabolism in a bid to maintain continuous cellular proliferation 
and growth, particularly under adverse conditions such as hypoxia (low oxygen availability) 
and cancer cell evasion from immune cell mediated attack and elimination 3. These 
alterations are enabled by two main characteristics, genome instability of cancer cells, which 
leads to random mutations that can enhance tumorigenic capabilities and a second enabling 
feature involves the inflammatory state of malignant and premalignant lesions that are 
orchestrated by cells of the immune system, promoting tumour progression 3. The 
multiplicity of innate anticancer defence mechanisms bypassed by cancer cells demonstrate 
the multistep progressive onset of cancer and indicate the complexity of the acquired traits. 
It is therefore clear that there are significant differences between normal and cancer cell 
Signalling pathways which present significant bottlenecks in current cancer research and 
anticancer strategies. Identification and understanding of these differences keeps us in line 
as we assemble the bits of the complex cancer puzzle. 
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1.1.1. Epidemiology 
Evidence of tumors found in fossilized dinosaur bones and the discovery of a 2700 year old 
human skeleton with clear signs of prostate cancer demonstrate that cancer has been around 
for a very long time, even though it is still a major health issue worldwide 4. Within the past 
century, cancer incidence and prevalence in various populations has dramatically increased 
and seems to be on the rise. These increases are most probably a result of a generalized 
increase in life expectancy and greater exposure to cancer-causing substances from various 
sources in the environment - such as: pollution from industrialization, tobacco use, fuel 
combustion emissions from automobile engines and exposure to ionizing radiation (X-rays) 
etc. 4,5. In 2012, the global number of new cases of cancer increased to about 14 million and 
it is expected to rise to an annual 19.3 million by 2025. The world’s most prevalent cancer is 
lung cancer, constituting 13% of the total number of cases in 2012, followed by breast cancer 
(11.9%), colorectal cancer (9.7%), and prostate cancer (7.9%). The most common cancer 
among men is lung cancer (16.7%), followed by prostate (15%) and colorectal (10%) cancers. 
Among women breast cancer  is the most common (25.5%), followed by colorectal (9.2%) 
and lung (8.7%) cancers 6,7. The highest number of cancer cases occur in the less developed 
areas of the world, with 60% of cancers and 70% of cancer related deaths occurring in Asia, 
Africa, and Central and South America 6. The greater prevalence in these regions can be 
linked to their large populations coupled to a lack of early detection and access to treatment 
which worsens the situation.  
Country specific data for Portugal are similar to the global picture. The most common and 
lethal cancers in Portuguese males are lung (19.3%), colorectal (15.3%), prostate (11.8%), 
stomach (9.7%), and pancreatic (4.8%) cancers. In Portuguese females, breast cancer is most 
prevalent (16.9%), followed by colorectal (16.4%), stomach (9.4%), lung (8.0%) cancers and 
lymphomas and multiple myeloma (6.2%) 8. 
Despite the marked exciting advances in cancer research, the global and individual country 
statistics indicate that cancer is still a major health problem nowadays and research efforts 
need to increase in order to meet up with the ever increasing challenges it presents. 
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1.2. Reactive Oxygen Species (ROS)    
Reactive oxygen species (ROS) are oxygen-containing chemical species that are produced as 
a result of incomplete reduction of oxygen (O2) and are highly reactive towards DNA, 
proteins and lipids. Biologically active ROS include hydrogen peroxide (H2O2), superoxide 
anion (O2 
-), and hydroxyl radical (OH.) which possess intrinsic chemical properties that 
make them reactive to different biological targets. H2O2 is the most abundant ROS in cells 
and has special characteristics that makes it a relevant second messenger in signal 
transduction pathways. Unlike O2 
– (which cannot readily travel across membranes by virtue 
of its negative charge), H2O2 can freely diffuse through membranes, making it an ideal 
intracellular signalling molecule – the main modulator of redox signalling 9. ROS are by-
products of protein folding, cellular respiration (oxidative phosphorylation at the 
mitochondrial membrane) and end products of some metabolic reactions such as the 
oxidation of long chain fatty acids in the peroxisome and reactions catalyzed by some 
enzymes such as such as xanthine oxidases, nitric oxide synthases, cyclooxygenases, 
cytochrome P450 enzymes, NADPH oxidases and lipoxygenases 10. Since ROS are much 
more reactive than O2, they were initially labeled as harmful mediators of cellular damage 
through protein oxidation, lipid peroxidation and DNA damage. However, recent research 
has demonstrated important roles for ROS as second messengers in cell signalling, being 
implicated in biologically important cellular processes such as growth factor signalling, 
hypoxic signal transduction, autophagy, immune responses, proliferation, differentiation, 
migration and apoptosis 10,11. This double-edge function of ROS appears contradictory 
considering the presence of highly robust and abundant cellular antioxidant systems 
including enzymes such as catalase, glutathione peroxidases, superoxide dismutases and 
thioredoxin peroxidases and systems that recycle the ROS scavenging proteins including the 
thioredoxin (TRX) and the glutathione (GSH) systems. However, it has been suggested that 
the concentration of ROS (H2O2) required for effective signalling is usually in the nanomolar 
range 11,12, whereas higher levels are associated with irreversible protein, lipid and DNA 
damage which could ultimately favor cancer initiation and progression (due to DNA 
mutagenesis) as well as other pathologies or cell death. Cellular ROS concentrations are 
therefore very tightly regulated and defective regulation could have devastating 
consequences. 
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1.2.1. Intracellular ROS production, regulation and signal transduction 
mechanisms 
ROS are produced as a result of incomplete reduction of oxygen as by-products of protein 
folding, cellular respiration (mitochondrial oxidative phosphorylation) and end products of 
metabolic reactions (figure 1a). By virtue of its relative stability, spontaneous membrane 
diffusibility, and selective reactivity towards critical cysteine (Cys) residues, H2O2 has been 
identified as the main mediator of ROS-dependent signal transduction 13. Most Cys residues 
in proteins have a pKa higher than 8.0 and will predominantly exist in the protonated thiol 
form (SH) at physiological pH (7.2 – 7.4). On the contrary, thanks to their local amino acid 
microenvironment, critical (reactive) Cys residues have a lower pKa (lower than 
physiological pH) and therefore predominantly exist as thiolate anions (S-) at physiological 
pH, making them extremely more reactive than the SH form and specifically and selectively 
susceptible to H2O2 induced oxidation 
14. The universally accepted ROS dependent signalling 
mechanism occurs through the H2O2-mediated oxidation of reactive Cys residues within 
redox-sensitive proteins which triggers or blocks various signalling cascades15. The selective 
oxidation of reactive Cys residues (which are only present in a very restricted subset of 
proteins referred to as redox-sensitive proteins) and strict  regulation and 
compartmentalization of H2O2 levels accounts for the specificity of redox signalling 
11. 
Optimal intracellular H2O2 levels (nanomolar range) provide an ideal environment for 
cellular signalling which maintains homeostasis in essential metabolic processes such as 
proliferation, differentiation and adaptation to metabolic and induced stress. However, supra-
optimal H2O2 concentrations trigger oxidative damage and abnormal cell signalling causing 
pathologies like cancer, among others, or even cell death. Sub-optimal H2O2 levels on the 
other hand lead to cell signalling disruptions which result in loss of homeostasis9  (figure 1b).  
1.2.1.1. Intracellular ROS production: 
Superoxide anion (O2 
-) can be produced as a result of the one-electron reduction of O2 by 
NADPH oxidases (NOXs) in the cytosol and in the mitochondrial electron transport chain 
(ETC) complexes I, II, and III 16,17. Mitochondria are thought to provide the lion's share of 
ROS in most cell types 10. Once produced, O2 
- is immediately converted onto H2O2 by 
superoxide dismutase 1 (SOD1) in the cytosol or extracellular matrix. Extracellularly 
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produced H2O2 can diffuse through the cell membrane to the cytosol, where it performs its 
functions. In addition, O2 
- generated by the ETC (complexes I and II) in the mitochondria is 
released into the mitochondrial matrix where it is rapidly converted onto H2O2 by superoxide 
dismutase 2 (SOD2) 18. ETC complex III-generated O2 
- is also released into the 
mitochondrial intermembrane space where it can cross through the voltage-dependent anion 
channels into the cytosol and where it is converted into H2O2 by SOD1 
19. Direct production 
of H2O2 in the mitochondria by p66
Shc-mediated direct two-electron reduction of molecular 
oxygen to H2O2  has also been reported
20. 
The very reactive hydroxyl radical (OH.), is produced  as a result of the reaction between 
H2O2 and metal cations (Cu
+ or Fe2+) through the Fenton reaction. Considering its very short 
half-life, lipid insolubility and strong oxidizing potential, the hydroxyl radical can cause 
irreversible oxidative damage to nearly any cellular macromolecule close to the area of its 
production. Since unrestrained levels of H2O2 lead to OH. formation, tight regulation of ROS 
(H2O2 in the nanomolar range) is critical for their role in redox-dependent signalling 
13 
(Figure 1b).  
Enzymes such as cyclooxygenases, xanthine oxidase, nitric oxide synthase, lipoxygenases 
and cytochrome P450 enzymes are also known to produce ROS to a lesser extent and their 
overall contribution depends on the cell type. Furthermore, the peroxisomes and endoplasmic 
reticulum have also been described as minor sources of ROS 10(Figure 1.1a). H2O2 is 
produced as an end product in several oxidation pathways in the peroxisomes such as in the 
β-oxidation of long-chain fatty acids, by a wide range of enzymes including cytochrome P450 
and as a by-product of protein oxidation in the endoplasmic reticulum (ER) 21. However, it 
is noteworthy that the specific targets of ROS are usually proximal in location to the ROS 
generating systems and their production is highly compartmentalized within specific cellular 
locations.  
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Figure 1.1: Intracellular sources (a) and regulation (b) of ROS. (a) Various organelles such as the 
mitochondria, the endoplasmic reticulum and peroxisomes as well as various enzymes, including oxidases and 
oxygenases, generate ROS as part of their enzymatic reaction cycles. (b) The produced O2– is rapidly converted 
into H2O2 by SOD1. H2O2 can either function as a Signalling molecule regulating several biological processes, 
including metabolic adaptation, differentiation, and proliferation, or be dismutated to H2O by ROS scavenging 
enzymes peroxiredoxin (PRDX), glutathione peroxidase (GPX), and catalase (CAT). H2O2 can also react with 
metal cations (Fe2+ or Cu+) to produce the hydroxyl radical (OH.), which causes irreversible oxidative damage 
to lipids, proteins, and DNA. Suboptimal H2O2 levels lead to a disruption of cell Signalling causing a loss of 
homeostasis, while supra-optimal H2O2 levels lead to oxidative damage and aberrant cell Signalling resulting 
in pathologies such as cancer 9,10,13. 
1.2.1.2 Intracellular regulation of ROS levels 
In order to curtail the accumulation of H2O2 and the acute toxicity of .OH, cells possess 
powerful antioxidant systems which temporally and spatially regulate intracellular ROS 
concentrations. The rapid SOD-mediated dismutation of O2
– to H2O2 prevents the 
accumulation of the highly reactive and damaging ROS, O2 
– 22, even though it leads to the 
production of another more stable ROS (H2O2). The enzymatic conversion of H2O2 to water 
(H2O) and O2 by antioxidants including glutathione peroxidases (GPXs), thioredoxin 
peroxidases (e.g. peroxiredoxins (PRDXs), annexin A2 and catalase), coupled with the GSH 
and TRX systems are together responsible for keeping H2O2 levels in check (Figure 1.1b). 
While catalase is only found in the peroxisomes of most cells, glutathione peroxidases 
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(GPXs), peroxiredoxins (PRXDs) and annexin A2 can be found in various cell compartments 
including the cytosol, mitochondria, nucleus and ER.  
Peroxiredoxins (PRDXs) are thioredoxin peroxidases that are divided into three classes: 
typical 2-cysteine peroxiredoxins (PRDX I-IV), atypical 2-cysteine peroxiredoxins (PRDX 
V), and 1-cysteine peroxiredoxins (PRDX VI). They are a highly abundant group of ROS 
scavengers which contain a conserved reactive Cys (referred to as the peroxidatic Cys (Cp) 
[Cys47] to indicate its sensitivity to peroxide oxidation) in their active site which is oxidized 
in the presence of H2O2 (forming a -Cys-SO
- intermediate or intra and inter-molecular 
disulfide bonds between the catalytic cysteine and the resolving cysteine) and subsequently 
reduced by the TRX system in every complete catalytic cycle. NADPH is then used as an 
electron donor for the thioredoxin reductase (TR) catalyzed reduction of the oxidized TRXs 
23. PRDXs are also special in their ability to undergo a reversible transient hyperoxidation 
mediated by a second H2O2 molecule, forming sulfinic acid (-Cys-SO2
-) which temporally 
inactivates the protein and favors ROS accumulation during signalling events, as will be 
elaborated later 24. Sulfiredoxin (SRX) reduces the hyperoxidized PRDX back to the -Cys-
SO- intermediate through an ATP- dependent reaction, making it available for further redox 
cycles 25. By virtue of their abundance, PRDXs are ideal candidates for scavenging of H2O2.  
Glutathione peroxidases (GPX1-8) catalyze the reduction of H2O2 by oxidizing the reduced 
form of glutathione (GSH) forming a glutathione disulfide (GSSG) which is reduced back to 
GSH by GSH reductase using NADPH as an electron donor 13. They have higher reaction 
rate constants but are less abundant than the PRDXs and are thought to be more implicated 
in H2O2 scavenging during oxidative stress (intracellular supraoptimal elevation of H2O2 
levels) 26.  
NADPH plays a critical rate limiting role in the production (through NOXs) and scavenging 
(electron donor in PRDXs and GPXs reactions) of ROS.  In spite of the high abundance of 
ROS scavengers, some H2O2 (nanomolar concentrations) manages to bypass these robust 
antioxidant systems to participate in signalling pathways. 
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1.2.1.3 Intracellular ROS (H2O2) mediated Signalling mechanisms 
By virtue of its selective specificity towards reactive Cys residues, spontaneous membrane 
diffusibility and stability, H2O2 is considered the main ROS involved in redox signalling. 
H2O2 carries out its signalling function by oxidizing reactive Cys residues within redox-
sensitive proteins 15. H2O2 molecules oxidize the thiolate anions to the sulfenic intermediate 
(SO-) which changes the conformation and activity of redox-sensitive proteins and thereby 
impacts on intracellular signalling. Supraoptimal H2O2 levels could lead to hyperoxidation 
of the SO- to form sulfinic (SO2
-) and sulfonic (SO3
-) acids. Hyperoxidation to SO3
- is 
irreversible and can be prevented by the rapid conversion of SO- into sulfenic-amide (S–N), 
disulfide (S–S) bonds, or glutathionylation. SO2- can be reduced back to the SO- intermediate 
by sulfiredoxin (SRX). The resulting oxidized proteins are restored to their reactive reduced 
state through the actions of TRXs and GRXs (figure 1.2a). Another well described, but less 
common post-translational oxidative modification of reactive Cys  is nitrosylation (RSNO) 
27. 
 
Figure 1.2: H2O2-mediatedoxidation of reactive Cys (a) and Signalling mechanisms 13. (a) 
H2O2 readily oxidizes the thiolate anions (S-) of reactive Cys yielding sulfenic acid (SO-) which modifies protein 
activity. High levels of H2O2 can lead to hyperoxidation to generate sulfinic (SO2-) and sulfonic (SO3-) acids 
(brown box). Oxidation to SO- and SO2- is reversed by TRX and SRX respectively. Formation of SO3- is 
irreversible and is prevented by the formation of reversible disulfide (S–S) or sulfenic-amide (S–N) bond (green 
box. (b) (i) The redox relay mechanism - ROS-scavenging proteins are initially oxidized by H2O2 and 
subsequently transfer the oxidation to the target protein. (ii) Floodgate mechanism - transient reversible 
inactivation of ROS scavenging proteins, allowing for localized accumulation of H2O2 for Signalling (iii) Redox 
relay mechanism with scavenging enzyme (TRX) as intermediate. (iv) Oxidative release mechanism – activation 
of target protein by dissociation from oxidized scavenging enzyme. 
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Recent studies have identified several mechanisms of H2O2-mediated oxidation of reactive 
Cys residues and signalling regulation, including: redox relay, floodgate, oxidative release 
and other likely mechanisms as described below. 
(i) The redox relay mechanism: 
In this mechanism, the ROS-scavenging proteins are initially oxidized by H2O2 and 
subsequently transfer the oxidation to target protein(s) causing activating or deactivating 
conformational changes (figure 1.2b (i)). For example, in response to H2O2, the apoptosis 
signal regulating kinase 1 (ASK1) protein is oxidized, leading to the 
phosphorylation/activation of the pro-apoptotic MAPKs, p38 and JNK. This occurs through 
the formation of a PRDX1–ASK1 mixed disulfide intermediate 28. Another redox relay type 
of mechanism has been proposed in which there is an intermediate step involving oxidation 
of the antioxidant proteins, PRDX, GSH or TRX prior to the transfer of the oxidation to the 
target protein or vice versa (figure 1.2b (iii)). An example of this type of redox relay was 
described in a study with 5’-AMP-activated protein kinase (AMPK), a redox sensitive kinase, 
where it was observed that, during energy starvation, AMPK molecules become oxidized and 
aggregate (by forming intermolecular disulfide bonds at Cys130 and Cys174 residues), which 
prevents its phosphorylation/activation by AMPK kinases. Here, TRX1 and/or PRDX 
supports AMPK activation by reducing these key residues, thereby permitting its activation 
for the regulation of metabolism and survival during energy stress 29. 
(ii) The flood gate mechanism: 
Another mechanism of H2O2 dependent signalling occurs through a transient reversible 
inactivation of ROS scavenging proteins, allowing for localized accumulation of H2O2 for 
signalling events 30,31 (figure 2b (ii)). It is proposed as a ‘flood gate’ model in the sense that 
the temporal inactivation of some key enzymes (e.g. PRDXs) causes local flooding of H2O2 
for signalling, while the other scavengers remain active to keep ROS levels in check and 
prevent non-localized diffusion of H2O2. The inactivation of these scavenging enzymes has 
been proposed to occur through temporal hyperoxidation 32 and/or phosphorylation 24 causing 
reversible deactivating conformational alterations. The unique ability of PRDXs to be 
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reversibly hyperoxidized to sulfinic acid (-Cys-SO2
-) coupled with the intracellular presence 
of the sulfinic scavenging enzyme (SRX) demonstrates the possibility of occurrence of this 
mechanism in vivo. Also, the in vivo existence of this model has been described in Zebra fish 
models33. 
(iii) The oxidative release mechanism: 
An additional proposed mechanism of H2O2-mediated signalling is the initiation of signalling 
by the activation of a target protein after its release from a complex with a redox regulatory 
enzyme. In this case, the antioxidant protein inactivates the target protein by direct binding. 
In the presence of H2O2 the antioxidant protein suffers an oxidative conformational change 
which severs the interaction, thereby activating the released target protein. This model has 
been described for the interaction between ASK1 (a pro-apoptotic protein) and TRX, 
whereby ROS-mediated separation of the aforementioned interaction releases ASK1 that can 
oligomerize and activate signalling pathways 34 .  
In line with the mechanisms described above, it is evident that in addition to their modulatory 
functions, the ROS scavenging enzymes may also be active sensors and transducers of redox 
signals, thereby participating actively in signalling events. The identification of the role of 
ROS in several metabolic signalling pathways coupled with the discovery of new redox-
sensitive proteins and elucidation of their signalling pathways is providing useful knowledge 
in normal and cancer cell signalling with useful applications in the development of anticancer 
networks. Further research into these signalling mechanisms and pathways will uncover more 
mysteries regarding the initiation, progression, treatment and prognosis of cancer. 
1.2.2. Physiological and metabolic outcomes of ROS-dependent Signalling 
One of the first demonstrations of a role for ROS as second messengers in cell signalling was 
the observation of a transient surge in ROS generation which precedes increases in tyrosine 
(Tyr) phosphorylation occurring after epidermal growth factor (EGF), platelet derived 
growth factor (PDGF), insulin, interleukin-1 (IL-1) and tumor necrosis factor–α (TNFα) 
stimulation 35,36. Since then, essential links have been established between growth factors, 
the production of ROS and Tyr phosphorylation, whereby the binding of growth factors to 
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their receptors leads to the activation of NOX which produces H2O2 for downstream 
signalling. 37. The detailed mechanism for growth factor induced generation of H2O2 and 
physiological effects are discussed in detail later in this work. Growth factor induced 
production of ROS affect downstream signalling pathways by ROS-mediated oxidation of 
reactive Cys leading to Tyr kinases and PTPs activation and inactivation, respectively. The 
oxidation of reactive Cys residues is also important as a means of regulation of the recently 
described large family of Cys-dependent proteases. For instance, H2O2-mediated inactivation 
of ATG4 (an essential autophagy protein) has been observed, which leads to augmented 
autophagosome formation 38. 
H2O2 is a second messenger in several signalling pathways regulating a variety of cellular 
processes, including proliferation, differentiation, metabolism, survival and apoptosis. Some 
examples of such pathways include the mitogen-activated protein kinase (MAPK) pathway 
and the phosphoinositide 3-kinase (PI3K) cascade which are activated in response to ROS 
resulting from growth factor stimulation and/or oxidative stress 39. Within the MAPK 
pathway, ASK1, an upstream MAPK kinase kinase, is activated through H2O2-mediated  
oxidation of TRX, leading to its dissociation from ASK1 which in turn becomes activated, 
resulting in downstream activation of the JNK and p38 MAPK signalling pathways leading 
to apoptosis in response to oxidative stress 40,41. The PI3K pathway plays a key ROS-
dependent role in cell proliferation and survival in response to growth factors, hormones, and 
cytokines stimulation. PI3K catalyzes the synthesis of phosphatidylinositol 3,4,5 
triphosphate (PIP3) from phosphatidylinositol 4,5 bisphosphate (PIP2), leading to the 
recruitment of protein kinase B (AKT) and further downstream signalling events that mediate 
proliferation and survival. Phosphatase and tensin homologue (PTEN) is a major negative 
regulator of this pathway by dephosphorylating PIP3 back to PIP2 
42,43. Here, through PTEN, 
the PI3K pathway is subjected to reversible redox regulation whereby H2O2 oxidizes and 
inactivates PTEN (via disulfide bond formation between the catalytic domain Cys-124 and 
Cys-71 residues) leading to the activation of the PI3K pathway 44,45.  
The identification of redox-regulated transcription factors has led to the elucidation of ROS-
mediated transcriptional regulation. One of the first examples of this type of mechanism was 
the description of the redox regulated DNA binding of the Fos-Jun heterodimeric 
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transcription factor complex. These studies showed that binding of Fos-Jun to the activator 
protein-1 (AP-1) DNA sequence motif was mediated by a conserved reactive cysteine residue 
located in the DNA-binding domains of Fos and Jun 46–48. This heterodimeric complex 
formed by Fos and Jun binds to transcriptional control elements containing AP- 1 binding 
sites and acts as an intermediary transcriptional regulator in signal transduction processes. 
Oxidation with diazenedicarboxylic acid bis [N,N-dimethylamide] was shown to inhibit the 
binding of Jun monomer and Fos-Jun heterodimer to DNA, an effect which was reversed by 
incubation with reducing agents, thereby confirming their redox regulation 47. Another 
example involves the forkhead box protein O (FOXO) family of transcription factors, 
whereby increased ROS levels favors redox-dependent interaction (formation of protein–
protein disulphide bridges) between FOXO4 and the nuclear import receptor transportin 1 
leading to nuclear import of FOXO4 and consequent activation of transcription of target 
genes mediated by this protein 49. Another example was presented in a study which described 
the redox-dependent activation of the nuclear factor erythroid 2-related factor 2 (Nrf2), which 
plays a major role in the protection of cells from xenobiotic and oxidative damage 50. Under 
normal physiological conditions, Nrf2 is rapidly degraded via the ubiquitin–proteasome 
pathway in a Kelch-like ECH-associated protein 1  (Keap1)-dependent manner whereby, 
Nrf2 is continuously ubiquitinated by the Cullin 3 (Cul3)–Keap1 ubiquitin E3 ligase complex 
leading to its proteosomal degradation 51. During oxidative stress, the reactive cysteine 
residues of Keap1 are oxidized, leading to stabilization of Nrf2 and its translocation and 
accumulation in the nucleus where it binds to antioxidant response elements (ARE) within 
the antioxidant genes promoters, thereby enhancing the overall cellular ROS scavenging 
capacity 50. Redox regulation of other transcription factors including NF-κB, STAT3, HIF-1 
and p53 has been also been described 52–56. The aforementioned transcription factors all 
possess reactive cysteine residue(s) within their DNA binding domains that can be readily 
oxidized by cellular ROS leading to loss of binding to their promoters/DNA. 
The enhancement of cellular ROS production by growth factor/growth factor receptor 
(GF/GFR) induced NOX activation has been adequately linked to increased rates of mitosis, 
cell transformation and tumorigenicity as demonstrated in NOX1 expressing NIH-3T3 
fibroblasts where coexpression of catalase and other antioxidant treatment reversed this 
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effect 57. Another study using NIH 3T3 cells transformed with H-Ras showed that these cells 
produced large quantities of ROS compared to control cells, which induced cell cycle 
progression and consequent proliferation in the absence of growth factors. This was reverted 
by treatment with the antioxidant N-acetyl-L-cysteine (NAC) 58. Supraoptimal concentrations 
of H2O2 can induce the upregulation of Fas expression (a death signal), increase intracellular 
ion uptake, and induce mitochondrial DNA damage , all of which can trigger apoptosis 59.  
ROS are therefore deeply and intricately involved in various signalling pathways as potent 
second messengers with various physiological outcomes in normal living cells. However, by 
virtue of the non-specific protein, lipid, and DNA damage caused by high levels of ROS, we 
can already predict their involvement in tumor initiation and progression (due to DNA 
mutagenesis and activation of proliferative and pro-survival signalling pathways).  
1.2.2.1 The role of ROS in cancer 
ROS play a complex role in cancer and have been implicated in the initiation and progression 
of several types of cancer. The uncontrolled proliferation and high metabolic rate of cancer 
cells leads to the production of high levels of ROS which keeps them in an almost permanent 
state of oxidative stress 60. In order to counteract the possible ROS-induced DNA, protein 
and lipid damage, cancer cells are known to up-regulate the expression of cellular antioxidant 
proteins. ROS-induced DNA damage, can lead to genomic instability which usually induces 
further increments in intracellular ROS levels, thereby effecting cellular senescence and 
apoptosis which can prevent genetically damaged cells from further proliferation and hence 
impede tumor formation. However, the up-regulation of antioxidants can on one hand be 
beneficial by reducing ROS levels and by doing so reducing DNA damage, while, on the 
other hand, they could help cancer cells to adequately bypass senescence or apoptosis, and 
consequently speed up tumor formation 10. ROS and antioxidant levels are therefore 
intricately connected to cancer cell metabolism and seem to have a double-edged sword 
function.  
ROS scavenging depends mainly on the availability of reducing equivalents provided by 
NADPH which is produced via the pentose phosphate pathway. The increased need for these 
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reducing equivalents in cancer cells pushes them to divert glucose metabolism towards the 
anabolic pentose phosphate pathway 61. Pyruvate kinase is a glycolytic enzyme that converts 
phosphoenolpyruvate (PEP) to ATP and pyruvate during normal homeostasis 61. Recently, it 
was reported that cancer cells express pyruvate kinase M2 ([PKM2] a specific redox-
sensitive isoform), and increased ROS levels target a reactive Cys residue in PKM2 which 
when oxidized leads to the inhibition of PKM2 and consequent diversion of glucose away 
from the normal catabolic pyruvate production towards the anabolic pentose phosphate 
pathway. This leads to increased NADPH production for redox buffering by GSH and other 
antioxidant systems, to compensate for the aberrant oxidative state 62. 
Another important link between cancer cell metabolism and ROS comes from recent studies 
of autophagy (cellular self-cannibalism). There is increasing evidence showing that part of 
the metabolic reprogramming in cancer cells involves upregulation of autophagy 10. 
Autophagy is mainly induced by starvation, which in turn leads to increments in intracellular 
ROS levels, which induce autophagy-mediated recycling of macromolecules and organelles 
to fuel mitochondrial metabolism in a bid to provide the much needed energy in the 
perpetually hungry cancer cells 63. This phenomenon was observed to be more common in 
Ras-expressing tumors whereby Ras triggers autophagy by ROS-induced hypoxia inducible 
factor (HIF-1α)-mediated activation of BNIP3 64. This ROS-induced autophagy-mediated 
stress response mechanism seems to be particularly important in cancer cells to provide 
energy and metabolic substrates, to recycle toxic damaged proteins and organelles and to 
limit cell death and tissue inflammation, thereby favoring survival and tumor growth. The 
clearance of damaged mitochondria (mitophagy), which are potential sources of ROS (which 
trigger cell death through ROS-induced necrosis), also occurs during autophagy further 
contributing to survival 65. ROS-induced autophagy addiction therefore stands out as a 
possible cancer cell survival mechanism as demonstrated by the energetically compromised 
state observed in autophagy-deficient cancer cells with tumorigenic mutations in Ras 
oncogenes under starvation 66. Another important outcome of ROS-induced autophagy-
mediated cancer cell survival under oxidative stress is the potential activation of autophagy 
as a chemotherapeutic and radiation resistance mechanism whereby ROS induce the 
assembly and maturation of the autophagosome which removes dysfunctional mitochondria 
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and proteins, as demonstrated in human hepatocytes 67. There are therefore strong links 
between the cancer cells’ autophagic flux, their intracellular redox state, growth, survival and 
resistance to chemotherapy and radiotherapy.  
Gain of function mutations in the PI3K pathway leading to its constitutive activation (and 
simultaneous ROS mediated inactivation of PTPs and PTEN) is a main mechanism of 
malignant tumor development and this pathway stands out as one of the most mutated in 
several types of cancer, with mutations that lead to cancer cell PI3K addiction, and 
understandably so, due to its sustaining effect on proliferation and survival 68. In this regard, 
the perpetual state of oxidative stress in cancer cells seems to be an advantage. The 
identification of a positive correlation between the RAS oncogene expression and increased 
ROS production with the observation of concomitant increases in proliferation in cancer cells 
transformed with Ras provided the first hints linking ROS with cancer and created avenues 
for further research 58. Here, NIH 3T3 cells transformed with a perpetually active isoform of 
Ras (v-H-Ras or EJ-Ras) were observed to produce large amounts of O2 
– and had higher 
rates of proliferation compared to control cells, an effect which was reversed by treatment 
with the chemical antioxidant N-acetyl-L-cysteine 58. 
ROS have also been implicated in metastasis, which stands out as a major piece of the cancer 
puzzle.  Mitochondrial ROS (mROS) production has been associated with the metastatic 
ability of cancer cells, as demonstrated in a recent study in which endogenous mitochondrial 
DNA (mtDNA) in poorly metastatic mouse tumor cell lines was replaced with mtDNA from 
highly metastatic cell lines, and vice versa. These studies showed that recipient cancer cells 
acquired the metastatic potential of the transferred mtDNA in vivo 69. The aforementioned 
acquired metastatic potential was confirmed to result from mtDNA mutations leading to a 
deficiency in respiratory complex I (NADH dehydrogenase) activity which favored the 
overproduction of ROS, leading to higher expression of the antiapoptotic MCL-1 (myeloid 
cell leukemia–1),  HIF-1α and VEGF neoangiogenic genes, creating the right environment 
for metastasis 69. A significant suppression of this effect was observed with pretreatment with 
ROS scavengers 69. These outcomes indicate the possible implication of mtDNA-mediated 
ROS production in metastatic tumor progression. In addition, as opposed to nuclear DNA, 
mtDNA is not protected by histones and is therefore more exposed to ROS, indicating a 
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higher rate of ROS-induced mtDNA mutagenesis compared to nuclear DNA which can be 
inherited by subsequent cellular generations, thereby favoring the evolution of the malignant 
phenotype 70,71. ROS-induced mitochondrial genome instability has also been associated with 
increased growth and invasiveness in colon and prostate cancers 72,73. This demonstrates an 
important role for ROS in cancer initiation through mtDNA mutagenesis. In another study 
with normal and prostate cancer cells, a significant increase in ROS generation was observed 
in cancer cells, with much higher levels in the more invasive PC3 cells indicating the critical 
role of ROS in promoting metastatic phenotypes which was confirmed by cyclin B–
dependent G2-M cell cycle arrest upon treatment with diphenyliodonium (NOX inhibitor) 
which impeded proliferation by modulating the activity of growth signalling pathways 
including extracellular signal-regulated kinase (ERK1/2), p38 MAPK and AKT 72.  
The ability of cancer cells to adapt to acute and chronic hypoxia is critical for their survival, 
especially in more advanced tumors which are subjected to a constant oxygen depleted state 
(hypoxia) 74. In this respect, hypoxia-induced mtROS-mediated signalling leads to the 
stabilization of the HIF-1α transcription factor which stimulates survival-supporting gene 
expression. This effect was confirmed by the mitochondrial intermembrane space (IMS)-
PRDX5 mediated inhibition of hypoxia-induced oxidant signalling and concurrent decrease 
in HIF-1α stabilization in pulmonary artery smooth muscle cancer cells overexpressing 
PRDX5 which led to decreased survival 74,75. 
In summary, as cells acquire a cancerous phenotype, they trigger ROS-dependent metabolic 
cascades that favor incessant proliferation, survival and metastasis leading to further ROS 
generation and keeping the cancer cells at a perpetual near toxic oxidative state 76. To curtail 
this, cancer cells often acquire a more glycolytic metabolism that increases NADPH 
production via the pentose phosphate pathway to ensure an adequate supply of reducing 
equivalents to support the cellular antioxidant systems in conjunction with the activation of 
redox-dependent transcription factors (e.g. Nrf2) which upregulate the expression of 
antioxidant proteins 62,77. 
Though not exhaustive, the information in the above paragraphs shows that ROS have varied 
effects on normal and malignant tumor cells, and further research is necessary to fill in the 
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knowledge and  mechanistic gaps in  ROS-mediated signalling in order to determine the 
precise role of ROS in cancer and other diseases and identify new potent therapeutic targets. 
1.3. Epidermal Growth Factor (EGF)-induced Signalling 
Pioneering research on the epidermal growth factor receptor (EGFR) pathways brought to 
light the widely used concept of linear signalling initiated by ligand-bound receptors and 
propagated downstream via multiple effectors78. Since its discovery in the early 1970s, 
epidermal growth factor (EGF) has been adopted as one of the most biologically potent and 
best characterized growth factor (at the physical, chemical, and biological levels) 78,79. 
EGF/EGFR signalling is one of the most capital pathways involved in the regulation of 
growth, proliferation, differentiation, and survival in normal and transformed cells and has 
been widely studied 80,81.  
As described in the pioneering work by Cohen and Carpenter as well as subsequent 
crystallography studies, human EGF (one of the 11 known human EGF-family ligands) is a 
53 amino acid single-chain polypeptide which contains six Cys residues that form three 
disulfide bonds and is encoded by a 4.8-kb mRNA transcript from a 110 kb long gene 
containing 24 exons and located on human chromosome 4q25 79,82–84. It is initially 
synthesized as a large (1207 amino acids) preproEGF molecule containing a hydrophobic 
signal peptide and an N-terminal transmembrane domain which has been shown to bind and 
stimulate EGFR on adjacent cells 85,86. The biologically active EGF peptide is produced by 
proteolytic cleavage of the N-terminal domain of the preproEGF which releases it for its 
autocrine or paracrine ligand function 86,87. EGF is expressed in several adult tissues and 
predominantly in the epithelial cells of the gastrointestinal tract 87. EGFR is a 1210 amino 
acid transmembrane glycoprotein which is a member of the ErbB family of receptor tyrosine 
kinases (RTK) which is constituted by four distinct receptors: the EGFR (ErbB-1/human 
epidermal growth factor receptor 1 [HER1]), ErbB-2 (neu, HER2), ErbB-3 (HER3) and 
ErbB-4 (HER4), all having a less conserved extracellular ligand-binding domain, a single 
hydrophobic transmembrane domain and a highly conserved cytoplasmic tyrosine kinase-
containing domain and are activated following binding of growth factors of the EGF-protein 
family which are usually released by autocrine or paracrine secretion 83,84,88,89. The receptor 
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therefore has two main functions: ligand binding and an intrinsic protein Tyr kinase activity 
(which includes autophosphorylation of the receptor in response to EGF binding) 90. Based 
on their ErbB-receptor binding, EGF-related peptide growth factors have been divided into 
three groups with the first group comprising EGF, amphiregulin, epigen and transforming 
growth factor α (TGF-α) which specifically bind to the EGFR; the second group includes 
heparin-binding growth factor (HB-EGF), epiregulin and betacellulin which are dually 
specific, binding both ErbB-4 and EGFR. The third group is composed by neuregulins, some 
of which bind only to ErbB-4 (NRG-3 and NRG-4) or  to ErbB-3 and ErbB-4 (NRG-1 and 
NRG-2) 86,91–93. The binding of EGF to the extracellular ligand-binding domain of EGFR 
prompts receptor dimerization, which normally brings the two cytoplasmic tyrosine kinase 
domains of the receptors in close proximity for autophosphorylation and consequent 
activation of the intrinsic tyrosine kinase activity 82. These phosphorylated residues serve as 
anchoring sites for Src homology 2 (SH2)-containing proteins and phosphotyrosine binding 
(PTB) domains which, when recruited trigger several downstream intracellular signalling 
pathways such as the Ras/Raf/ MAPK (proliferation) and the PI3K/Akt pathways 
(proliferation and survival) 94. Interestingly, ROS have also been implicated in apoptosis, 
mainly during oxidative stress. Endogenous H2O2, produced by the mitochondria and low 
density lipoprotein oxidation was observed to induce apoptosis via JNK activation in cells in 
conjunction with upstream Src-dependent activation of EGFR 95,96. 
Considering the importance of the physiological effects of EGF-induced signalling in the 
maintenance of cancer and its hallmarks, it would be logical to expect its involvement in the 
initiation and progression of various cancer types 87. Also, considering the various 
components of the pathways activated by the EGF/EGFR interaction, it is noticeable that 
these are dependent in a large part on ROS signalling, as described in previous sections of 
this thesis. It would therefore be expected that EGF binding would lead to signalling events 
that trigger the production of ROS as potent second messenger signal transducers which 
further activate other signalling pathways with various physiological outcomes. 
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1.3.1. EGF-induced ROS production 
Several ligands have been identified that carry out their signalling functions by stimulating 
the production of H2O2. These include peptide growth factors such as EGF, PDGF, basic 
fibroblast growth factor (bFGF), granulocyte-macrophage colony- stimulating factor (GM-
CSF) and insulin; heterotrimeric guanosine 5′-triphosphate (GTP)-binding protein (G 
protein)-coupled receptors (GPCRs) agonists such as thrombin, angiotensin II, thyrotropin, 
lysophosphatidic acid (LPA), parathyroid hormone, sphingosine 1-phosphate, endothelin, 
serotonin, acetylcholine, bradykinin and platelet-activating factor; and cytokines such as 
interferon-γ, transforming growth factor-β (TGF-β1), interleukins 1 and 3, TNF-α and the T 
cell antigen receptor 36. However, the ubiquitous involvement of EGF/EGFR and its 
homologues in a wide range of malignancies 97–99 as ROS-mediated drivers of some of the 
main hallmarks of cancer makes it an appropriate candidate for our present study.  
As described in the above paragraphs, the initial triggering events in response to EGF/EGFR 
interaction involve the activation of tyrosine kinase activity followed by several downstream 
events mediated by H2O2 
82. This possibility led Bae et al. to investigate EGF-induced ROS 
generation and its role in tyrosine phosphorylation, which was one of the first studies in 
which EGF stimulation was adequately associated with ROS generation for signalling, 
especially in the ever active cancer cells 35. In the aforesaid study, it was unambiguously 
ascertained that EGF induces ROS production as demonstrated in A431 human epidermoid 
carcinoma and NIH 3T3 cells whereby significant increases in 2’,7’- 
dihydrodichlorofluorescein diacetate (DCFH-DA) fluorescence were observed after five 
minutes of EGF treatment. This result was confirmed to be primarily attributable to H2O2 on 
the basis of the disappearance of dichlorofluorescein (DCF) fluorescence after introduction 
of catalase (H2O2 scavenger) into the cells by electroporation. In addition, the tyrosine 
phosphorylation of EGFR and phospholipase C-ɣ1 after EGF-induction was completely 
blocked in A431 cells containing exogenous catalase indicating a reliance of the tyrosine 
phosphorylation of the aforementioned proteins on EGF-induced increases in H2O2 levels 
35. 
Also, in order to gain more insight into the role of the EGFR activity and/or 
autophosphorylation sites in EGF-induced ROS production, cell lines expressing either the 
wild-type EGFR, a truncated EGFR without the C-terminal 126 amino acids (CD-126 EGFR 
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[absence of four out of five autophosphorylation sites]) or a tyrosine kinase-negative EGFR 
were treated with EGF, after which significant increases in H2O2 levels were observed in the 
wild-type or CD- 126 EGFR but not in the cells with the catalytically inactive mutant 
suggesting that the receptor tyrosine kinase activity, and not necessarily autophosphorylation 
is needed for the EGF-induced ROS production. Furthermore, it was also hypothesized in 
this study that since all PTPs contain a reactive Cys moiety in their active site PTPs may be 
targets of EGF-induced intracellular H2O2 
35,100. This hypothesis was confirmed in later 
studies in which the inhibition of PTEN (tumor suppressor) and PTPs was observed in 
various cell types and was confirmed to result from H2O2-mediated oxidation of their 
catalytic Cys residues in response to EGF and/or PDGF stimulation 44,101–104.  
A precise mechanism for EGF-induced H2O2 generation and initiation of signalling events 
has been recently proposed by various studies, in which the stimulation of cells with EGF 
leads to the activation of PI3K, which phosphorylates PIP2 forming PIP3. PIP3 then activates 
guanine nucleotide exchange factors such as Ras which activate the Rac proteins (exchange 
of Rac-bound GDP for GTP) leading to the assembly and concomitant activation of the 
NOX1 complex, resulting in the production of O2 
– that is then converted to H2O2 by SOD. 
The H2O2 so produced mediates the transient inactivation of neighboring cytoplasmic PRDX 
molecules by reversible hyperoxidation which in turn promotes local accumulation of H2O2. 
The accumulated H2O2 molecules oxidatively inactivate PTEN (by causing the formation of 
a disulfide bond between Cys124 and Cys71 in its active site) and PTPs (e.g. PTP1B and 
SHP2 by oxidation of the conserved reactive Cys present at the catalytic site). The 
inactivation of PTEN leads to further increases in the levels of PIP3 which triggers 
downstream signalling pathways such as the PI3K-AKT and Ras-ERK pathways with 
physiological effects such as proliferation, differentiation, growth, migration,  survival, 
angiogenesis and metastasis 32,36,44,103,105,106. In addition, EGFR has also been reported to have 
a reactive Cys in its active site (Cys-797), which, when oxidized, enhances its Tyr kinase 
activity and subsequent signalling, indicating a positive feedback function of the EGF-
induced H2O2 on EGFR 
106. The H2O2 signal is then quenched by the reactivation of PRDXs 
and the resultant scavenging of H2O2 in combination with  the  NADPH-dependent 
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reactivation of oxidized PTEN by TRX, restoring its 3-phosphatase function 
(dephosphorylation of PIP3 to PIP2) 
32,36,44,103,105,106 (figure 1.3).  
 
Figure 1.3: Mechanism for EGF-induced H2O2 generation and initiation of Signalling 
events106. EGF binding to EGFR induces receptor autophosphorylation, leading to activation of PI3K, which 
phosphorylates PIP2 forming PIP3. PIP3 through several steps activates NOX which generate H2O2 which 
oxidizes and inactivates PTEN and other PTPs, leading to increased phosphorylation and activation of 
downstream Signalling. Oxidation of EGFR by H2O2 also potentiates its kinase activity. H2O2 signal is 
quenched by the reactivation of hyperoxidized PRDXs and oxidized PTEN by SRX and TRX respectively. 
Summarily, the binding of EGF to EGFR perpetuates downstream cellular signals through 
ROS-mediated activation of receptor Tyr kinases (RTKs), oxidative activation of EGFR, 
oxidation and concurrent reversible transient inhibition of PTPs and PTEN (which prevents 
futile phosphorylation/dephosphorylation cycles) leading to the activation of downstream 
pathways that maintain proliferation, differentiation, growth, migration, survival, 
angiogenesis and metastasis 44,103,106,107.  
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1.3.2. EGF-induced Signalling pathways 
 
Figure 1.4: EGF-induced signalling pathways and physiological outcomes (adapted and 
simplified) 108. ‘Snap shot’of EGF-induced Signalling pathways and physiological consequences. 
 
1.3.3. EGF/EGFR involvement in cancer 
Over the years, EGF/EGFR signalling has moved to the forefront of cancer research and 
therapeutic targeting, and rightfully so, following early reports of elevated EGFR levels in 
clinical samples from both human head and neck squamous cell carcinoma and lung 
squamous cell carcinoma 109. Other subsequent studies confirmed the aberrant expression of 
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EGFR (especially the intracellular Tyr kinase domain) and its ligands in various cancers, 
confirming its ubiquitous implication in cancer etiology and prognosis 87,94. The gain of 
function genetic alterations that have been detected in human cancers include gene 
amplification leading to overexpression of EGFR and EGF, kinase domain mutations which 
activate EGFR, in-frame deletions in the EGFR extracellular domain, and co-expression of 
ErbB ligands and receptors in tumors 110,111. Each of the aforementioned alterations leads to 
constitutive receptor activation, which, together with the consequent ROS production and 
other factors downstream drive cancer initiation and progression 93. A typical example is the 
observation of EGFR overexpression in about 80% of head and neck tumors correlating with 
poor prognosis and resistance to chemotherapy 112. Another example is the multiple short 
deletions identified within the β3–αC loop of the EGFR kinase domain and also within the 
activation loop, P-loop, αC–β4 loop and mutations of Gly719 and Leu858 in several lung 
cancers which affect regulatory regions and result in enhanced kinase activity, or aberrant 
substrate specificity and consequent increases in ROS for downstream second messenger 
Signalling113,114. 
The PI3K/AKT pathway (direct target of EGFR) is one of the main constitutively active and 
therapeutically targeted EGF/EGFR stimulated signalling pathways in cancer which 
promotes growth, survival, proliferation and resistance to chemotherapy in cancer cells. 
Interestingly, all of the major upstream elements of this pathway have been found mutated 
or amplified in a plethora of cancers 68. Gain of function mutations in PIK3CA, the gene 
encoding the p110α catalytic subunit of PI3K have been identified which enhance oncogenic 
PI3K signalling and, together with PIK3CA amplification, PTEN loss, AKT mutations and 
RTK amplification constitute frequent genomic alterations that promote tumorigenesis by 
upregulating the PI3K/AKT signalling axis in various tumors 68,115. It is however noteworthy 
that EGF-induced growth and survival signalling is not trivial and involves complex 
networks with redundancies (several proteins with the same physiological effect), additive 
and synergistic effects which provide escape routes for cancer cells when treated with Tyr 
kinase inhibitors. This implies that it may be useful to target ROS levels and ROS modulators 
(e.g. annexin A2) in these pathways in combination with existing therapies for better 
outcomes.  
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From the above paragraphs, we can infer that EGF-induced ROS-mediated signalling 
addiction is common in a wide range of cancers with varied physiological effects which tend 
to be advantageous to cancer cells. To this respect, more research is necessary to better 
understand, the various components of these pathways and their alterations in tumor cells. In 
addition, recent evolution of resistance to existing therapeutics has created a need for novel 
strategies, and the direct and/or indirect control of ROS levels could be an option. Mindful 
of ROS scavenging ability of annexin A2 116 and the ROS generating ability of EGF/EGFR 
35, investigating the role of annexin A2 in EGF-induced signalling in cancer will provide 
useful insights in cancer biology and could create avenues for the development of novel more 
effective therapeutic regimens. 
1.4. Annexin A2 (ANXA2) 
The annexins belong to a family of structurally related proteins (in vertebrates: annexin A1- 
A13) that bind anionic phospholipids in a calcium (Ca2+)-dependent manner 117. The basic 
structure of the annexins consist of a variable N-terminal domain containing various sites for 
protein-protein interactions and post-translational modifications which is responsible for the 
unique functions of each annexin, and a highly conserved C-terminal domain which is 
typically composed of four homologous domains (I - IV) (with the exception of annexin A6 
that has eight of these domains), each consisting of five α-helices (A–E) with the AB and DE 
helices being connected by loops (AB and DE loops). One or more of these domains I–IV 
contain the endonexin fold (a region of homology) which is considered to be the signature 
amino acid sequence for the annexins, containing the calcium-binding motif (KGXGT-38 
residues—D/E) and is present in at least one of the four AB loops 118. The unique feature that 
distinguishes annexins from other calcium-binding proteins is their calcium-dependent 
reversible binding to negatively charged cellular membranes 119. The tissue distribution and 
level of expression of annexins span from relatively abundant and ubiquitously expressed 
annexins (A1, A2, A4, A5, A6, A7, A11) to selective (annexin A3 in neutrophils and annexin 
A8 in the placenta and skin) or restrictive (annexin A9 in the tongue, annexin A10 in the 
stomach and annexin A13 in the small intestine) 120. The annexins have also been implicated 
in a wide variety of intracellular membrane related functions such as exocytosis (annexins 
A2 and A7), endocytosis (annexins A1, A2 and A6), as membrane scaffolds (annexins A1, 
27 
 
A2, A4, A5 and A7), membrane reorganization (annexins A2, A3, A5 and A11), vesicular 
trafficking (annexins A2 and A11), regulation of ion transport across membranes (annexins 
A2, A4 and A6), and redox regulation (annexin A2) as well as extracellular functions such 
as their regulation of inflammation and apoptosis (extracellular annexin A1), fibrinolysis 
(annexin A2) and coagulation (annexin A5) 117,119,121. 
1.4.1. Structure and functions of ANXA2 
Annexin A2, (which is also referred to as p36, ANXA2, annexin II, lipocortin II, calpactin I 
chromobindin VIII, or placental anticoagulant protein IV), is a 36 kDa protein of the 
vertebrate annexin family located on chromosome15q22.2 122,123. It is expressed in various 
cells including monocytes, macrophages, endothelial cells and most cancer cells, where it is 
distributed mainly in the cytoplasm and plasma membrane with a small proportion in the 
nucleus 124,125. ANXA2 was first identified as a substrate for the tyrosine kinase v-Src, the 
gene product of avian sarcoma virus which promotes cellular transformation 126. This 
discovery already gave some hints for its possible involvement in cancer and various diseases 
as confirmed in recent research. 
Like other annexins, the basic structure of ANXA2 consists of a homologous C-terminal core 
composed of four 70 amino acid repeats with five α helices, and a highly variable N-terminal 
tail. The C-terminal core contains the Ca2+, phospholipid, F-actin and heparin binding sites, 
while the N-terminus contains the S100A10 (p11) binding site, a nuclear export sequence 
(Val-3-Leu-12), an acetylation site (Ser-1) as well as several phosphorylation sites such as 
Ser11, Tyr23 and Ser25, which can be phosphorylated by Src kinase (proto-oncogene) and 
protein kinase C, respectively, which influences its localization and functionality in some 
cell types 118,123,127 (Figure 1.5a). Furthermore, ANXA2 has been identified as a novel cellular 
redox regulatory protein by virtue of possessing a reactive cysteine residue (Cys-8) in the N-
terminus which, together with the reducing effect of the TRX system has been proven to 
participate in normal and cancer cell redox metabolism and is the raison d'être of this study 
116,128. The calcium-dependent activation of ANXA2 leads to a conformational change that 
exposes some hydrophobic amino acids (Val-3, Ile-6, Leu-7 and Leu-10) priming the 
formation of a heterotetramer complex with its binding partner, S100A10, called ANXA2-
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S100A10 heterotetramer (AIIt). AIIt shows a high affinity for phospholipids via the ANXA2 
subunit of the complex 129. ANXA2 has been shown to exist as a monomer, heterodimer 
(composed of one molecule of ANXA2 and a molecule of 3-phosphoglycerate kinase) or as 
a heterotetramer consisting of 2 molecules of ANXA2 bound together by a dimer of S100A10 
which possesses a range of biological functions 130–132. The ANXA2 monomer is mainly 
cytosolic while the other forms are predominantly membrane bound and each of the different 
forms have been shown to have various functions. Formation of the heterodimer results in 
the association of the resultant complex with the nucleus where it has been revealed to 
regulate DNA polymerase α 130. The nuclear accumulation of the ANXA2 monomer has been 
reported to play a role in protecting cells from DNA damage during oxidative stress induced 
by genotoxic agents such as UV radiation, etoposide, chromium VI and gamma-radiation 133. 
The most extensively studied and well documented function of AIIt on the extracellular 
surface is its interaction with tissue plasminogen activator (tPA) and its substrate, 
plasminogen, whereby it promotes the conversion of plasminogen into plasmin 130,134,135 by 
which it regulates fibrinolysis 122,136, facilitates tissue remodeling, degrades extracellular 
matrix and participates in angiogenesis 137,138. The functions of AIIt are summarized in the 
schematic diagram in figure 1.5b. In addition to the aforementioned functions, Kwon et al., 
139 demonstrated that extracellular ANXA2 binds to and reduces the serine protease plasmin 
and that ANXA2 oxidized during this reaction is subsequently reduced by the TRX redox 
system. This study provided hints to the possibility of a redox signalling or redox regulatory 
function for ANXA2 and led to follow up studies of which the present study is part. 
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Figure 1.5: Annexin A2 domain structure (a) and functions of annexin A2 and AIIt (b) 
(adapted) 118. (a) The N-terminus of annexin A2 is the site for post-translational modifications including 
acetylation (S1) and phosphorylation (S11, Y23 and S25). It also contains the reactive cysteine residue (C8), 
the NES (V3-L12) and the hydrophobic residues, V3, I6, L7 and L10 which bind to S100A10. The C-terminal 
domain includes four 70 amino acid α-helices and contains binding sites for heparin, RNA, phospholipids, Ca2+ 
and F-actin. (b) Schematic diagram summarizing the functions of annexin A2 monomer and heterotetramer.  
1.4.2. ANXA2 in redox regulation 
A unique feature which makes ANXA2 stand out among the annexins is the fact that it has 
redox sensitive cysteine(s) which qualify it to participate in redox homeostasis. The aforesaid 
role of ANXA2 in redox regulation of plasmin, coupled with the presence of redox sensitive 
cysteine(s) on ANXA2 that can participate in redox cycles as well as its ubiquitous and 
abundant cellular expression led Madureira et al., 116 to postulate and confirm the cellular 
redox regulatory role of this protein. In the aforementioned study, Cys8 of ANXA2 was 
identified as the redox sensitive cysteine of ANXA2 that can be reversibly oxidized by H2O2 
and subsequently reduced by the TRX redox system, participating in this way in several redox 
cycles. In addition, ANXA2 depleted cells were shown to display higher levels of ROS, 
increased activation of the ROS-induced pro-apoptotic kinases: JNK, p38 and Akt compared 
to control cells and consequent higher sensitivity to oxidative stress-mediated cell death. In 
addition, ANXA2 depleted cells were also significantly more sensitive to death induced by 
chemotherapeutic agents that produce ROS as part of their mechanism to kill cancer cells. 
The redox regulatory role of ANXA2 was further confirmed in vivo with the demonstration 
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of a notable increase in the oxidation of proteins in the liver and lung tissues of ANXA2- null 
mice compared to WT mice. In addition, a severe impairment of tumor growth was observed 
in tumors resulting from the subcutaneous injection of ANXA2-depleted human cancer cell 
lines (HT1080 and A549) in mice, compared to control cells, an effect that was reversed by 
the intraperitoneal administration of the antioxidant N-acetyl cysteine (NAC) to the mice 
during tumor development. Furthermore, ex-vivo experiments using human colon tumor 
samples showed that the cancer samples expressed significantly higher levels of the reduced 
form of ANXA2 in contrast to normal matched tissues and that the up-regulation of the levels 
of reduced ANXA2 correlated with protection from oxidation of the proteins in these tumors, 
indicating a possible redox regulatory role for ANXA2 in human tumors. This study led to 
the proposal of a mechanistic model in which H2O2 reacts with the Cys8 of ANXA2 resulting 
in its oxidation and the dismutation of H2O2 to H2O. The oxidized ANXA2 is then reduced 
by the TRX redox system, which permits it to participate in further redox cycles 116 (Figure 
1.6). Another recent study identified an important role for the ANXA2 monomer in 
mitigating DNA damage in response to genotoxic agents by its ROS-dependent nuclear 
accumulation mediated by the inactivation of ANXA2 nuclear export sequence (NES) 133. 
ANXA2 is therefore part of the redox proteome and more so in cancer cells, where it will be 
more relevant to mitigate the possible detrimental effects of the perpetual oxidative stress. 
 
Figure 1.6: Redox mechanism for ANXA2 (adapted) 116. The oxidation of Cys8 of ANXA2 by H2O2 
leads to the conversion of H2O2 to H2O. The oxidized ANXA2 is then reduced by the TRX redox system and 
can participate in additional redox cycles. A single molecule of ANXA2 can therefore participate in several 
redox cycles. 
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1.4.3. ANXA2 in cancer 
ANXA2 is aberrantly expressed in a plethora of tumors. Increased expression of ANXA2 
protein and mRNA has been observed in many malignancies such as hepatocellular140 and 
gastric carcinomas 141, colorectal 142, breast 143, lung 144 and pancreatic cancers 145, 
particularly in the more aggressive or poor prognosis phenotypes 146,147. ANXA2 
overexpression has also been positively correlated with resistance to chemotherapy and 
malignant progression 145,148,149.  
The high expression of ANXA2 in tumor stroma and cancer cells has been associated with 
the enhancement of tumor cell adhesion 127. A recent example supporting this association is 
the demonstration that the adhesion between breast cancer cells and endothelial cells (ECs) 
is mediated by interactions between ANXA2 and S100A10 in a mechanism whereby ANXA2 
expressed on the surface of the cells interacts with S100A10 located on microvascular ECs 
and facilitates the process by which these cells form cell-cell contact with microvascular ECs 
which is important for tumor growth 150. 
ANXA2 plays a role in the enhancement of proliferation and inhibition of apoptosis through 
different pathways in a number of cancer cell types. This role has been observed in a study 
which showed that, during oxidative stress ANXA2 depleted MCF-7, A549, HT1080 and 
LLC cell lines exhibited significantly greater levels of P-p38, P-Akt and slightly elevated P-
JNK compared to control cells, consistent with the susceptibility of these cells to oxidative 
stress (ROS) induced apoptosis, indicating a ROS-mediated anti-apoptotic role for ANXA2 
116. Another study by Madureira et al., demonstrated that,  in response to genotoxic agents 
(such as gamma-radiation, UV radiation, chromium VI and etoposide), cells depleted of 
annexin A2 had enhanced p53 (transcription factor which regulates cell cycle 
arrest/apoptosis) levels, increased phosphorylation of histone H2AX (indicator of DNA 
damage) and increased numbers of p53-binding protein 1 nuclear foci suggesting that 
annexin A2 could play an anti-apoptotic role by mitigating DNA damage (a role which was 
confirmed to be ROS-dependent) 133.  Furthermore, other studies showed that silencing of 
ANXA2 expression in lung cancer (A549) cells, human hepatocellular carcinoma and breast 
cancer (JIMT-1 and MDA-MB-231) cells coupled to treatment with a JNK inhibitor 
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(SP600125) led to a significant inhibition of proliferation with a marked decrease in the 
percentage of cells in the S/G2+M phase  of the cell cycle and an increase in p53 transcription 
with more cells found to accumulate in the G0/G1 phase compared to control cells 
(expressing normal levels of ANXA2) 151–154.  
ANXA2 and AIIt also play a major role in tumor progression by enhancing 
neovascularization. An increase in the expression of AIIt in some tumors has been recognized 
as a major contributor to cancer angiogenesis in vitro and in vivo 155,156. Recent studies using 
xenograft models of human breast tumors have demonstrated a marked inhibition of 
neoangiogenesis in the tumor microenvironment after treatment with an ANXA2 antibody, 
indicating the active participation of ANXA2 in the formation of new blood vessels in cancer 
157. Another study with clinical samples demonstrated the accumulation of tPA and AIIt on 
the surface of invasive human breast cancer cells which was positively correlated with tumor 
neovascularization 138.  
Tumor invasiveness and metastasis is the major cause of mortality among cancer patients. 
The involvement of ANXA2 in tumor invasion and metastasis by interacting with the actin 
cytoskeleton and potential invasion-associated proteases has been reported in many late-stage 
human tumors 127. A simple example was described in a study whereby the overexpression 
of ANXA2 was observed in the highly invasive MDA-MB-231 breast cancer cell line 
compared with the poorly invasive MCF-7 cell line 143. In addition, the administration of 
adriamycin MCF-7/ADR to the cell cultures has been observed to increase the expression of 
ANXA2 with a resultant enhancement of cell proliferation and invasion, suggesting the 
association of ANXA2 in cancer cell invasion 158. Also, ANXA2 knock down by siRNA or 
neutralizing antibodies has been observed to significantly inhibit the motility and invasion of 
HCC and other cancers, further indicating the contribution of ANXA2 to metastasis 152,159. 
S100A10 in AIIt catalyzes the conversion of plasminogen to plasmin through its interaction 
with tPA and thus efficiently enhances the effects of plasmin tissue remodeling, matrix 
metalloproteinases and latent growth factor activation, and extracellular matrix degradation, 
leading to tumor progression and metastasis 122,160. Furthermore, upregulation of ANXA2 in 
MCF-7 non-invasive breast cancer cells has been observed to increase the expression of c-
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myc and cyclin D1 by activating the Erk1/2 signalling pathways leading to enhanced 
migration and invasion in vitro and in vivo 161. 
From the above paragraphs, we can see that ANXA2 is an important molecule involved in 
regulating tumor cell adhesion, proliferation, invasion, metastasis, tumor neovasculogenesis 
and redox homeostasis, thus playing a crucial role in the multistep process of tumor 
development. However, many gaps still exist in the knowledge of the specific biochemical 
mechanisms and signalling pathways that bring about the aforementioned physiological 
effects of ANXA2 in cancer. In addition, considering the importance of ROS in the 
physiological outcomes of ANXA2 mentioned above, it is important for us to gain more 
insight into the ROS-mediated effects of ANXA2 in a bid to fill in the gaps and contribute to 
the identification of novel anticancer strategies. 
1.5. Rationale 
As mentioned earlier in this thesis, ROS are produced as a consequence of cellular 
metabolism and can also be produced by the cell in response to GF/GFR stimulation to 
function as second messengers in major signalling pathways. Even though ROS play very 
important roles in cell signalling events, their levels and intracellular localization must be 
tightly regulated within the cell (nanomolar levels required for signalling), since increased 
production of these highly reactive small molecules can be detrimental, leading to protein 
oxidation, lipid peroxidation and DNA damage, giving rise to cell death and/or tumorigenesis 
(in case of DNA mutagenesis). Consequently, the robust cellular redox systems play a critical 
role in regulating homeostasis and cellular integrity in normal and cancer cells by regulating 
the restricted sub-cellular location of ROS and ROS signalling events.  Thanks to their ever 
active metabolic state and to the tumor microenvironment, cancer cells are in a perpetual 
state of oxidative stress and tend to up-regulate ROS scavenging systems in order to strike a 
balance between the ROS concentrations required for signalling and the detrimental effects 
of high ROS levels. Unravelling new members that contribute to cellular redox equilibrium 
will provide valuable tools to fight against the harmful effects of ROS in normal cells and 
create avenues to preferentially and specifically target cancer cells. The EGF/EGFR ligand-
receptor system is ubiquitously up-regulated in most cancers whereby it enhances 
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downstream signalling events that favor the development of various aspects of the cancer 
phenotype. The binding of EGF to EGFR leads to signalling events that trigger the production 
of ROS (H2O2) as potent second messenger signal transducers which further activate other 
signalling pathways with various physiological outcomes. A majority of the downstream 
effectors of EGF/EGFR signalling are dependent on ROS, as described in previous sections 
of this write up. The overexpression of ANXA2 is commonly observed in a large number of 
cancers where it enhances the development of the main specific features of cancer. Madureira 
et al., recently identified a novel function for ANXA2 as an antioxidant protein by virtue of 
its possession of a reactive Cys (Cys8) residue which participates in many redox cycles and 
it is recycled by the TRX system. This study also demonstrated that the redox regulatory 
function of ANXA2 enhances tumor growth and resistance to chemotherapy 116. As a logical 
follow up of the aforesaid findings, investigating the role of ANXA2 in ligand/receptor-
induced ROS-dependent signalling is necessary to further understand the redox regulatory 
function of ANXA2 and gain more insight in cancer cell signalling.  
1.6. Objectives 
1.6.1. Main objective 
The main aim of this study is to investigate the role(s) of the novel antioxidant protein, 
ANXA2 in EGF/EGFR-induced ROS-dependent signalling pathways in cancer cells. 
1.6.2. Specific objectives 
In order to achieve the main objective I propose to achieve the following specific objectives: 
(i) Analyse the activation of signalling pathways in ANXA2 shRNA (knockdown) 
versus control (scramble shRNA) cancer cells upon activation with EGF to 
investigate if ANXA2 plays a role in the regulation of EGF/EGFR induced signalling 
pathways. 
(ii) Assess the oxidation of reactive Cys residues in redox-sensitive signalling proteins 
pathways in ANXA2 shRNA (knockdown) versus control (scramble shRNA) cancer 
cells upon activation with EGF. 
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(iii)Analyse the ROS levels of ANXA2 shRNA (knockdown) versus control (scramble 
shRNA) cancer cells upon activation with EGF to investigate if ANXA2 plays a role 
in ROS inactivation upon EGF/EGFR induced signalling. 
(iv) Analyse if ANXA2 is important for cell proliferation induced by the EGF/EGFR 
signalling pathways. 
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2. MATERIALS AND METHODS 
2.1. Cell culture and cell lines 
All cell lines used in this study had been previously transfected with ANXA2 shRNA 
(knockdown and scramble). The cell lines used for this study and their respective information 
are summarized in table 2.1. The cells were all confirmed to be mycoplasma negative. The 
cells were cultured in complete Dulbecco’s modified Eagle’s medium162 (HyClone™) 
supplemented with 10% fetal bovine serum (FBS) [SIGMA®], 100 U/ml of 
penicillin/streptomycin (SIGMA®) and 2 mM of L-Glutamine (SIGMA®) in a humidified 
incubator (Forma™ Series II Water-Jacketed CO2 Incubators - Thermo Scientific) in an 
atmosphere of 5% CO2 at 37º C.  
Cell stocks were taken out from the -150 °C deep freezer (SANYO), left to thaw in an 
unstirred water bath (Clifton) at 37⁰C after which they were placed in 10 ml of pre-warmed 
complete Dulbecco’s modified Eagle’s medium (DMEM) in 15 ml falcon tubes (VWR) and 
centrifuged for 5 minutes at 1000 g. The medium was aspirated to remove the dimethyl 
sulfoxide (DMSO) [which is toxic to the cells] and the pellets containing the cells were re-
suspended in 5 ml or 15 ml of complete medium dispensed into T25 (VWR) or T75 (Greiner) 
culture flasks, respectively. Puromycin (10 mg/ml, SIGMA®) was added to each culture flask 
in a ratio of 1:5000 (final concentration of 2 µg/ml) in order to selectively obtain the desired 
phenotypes after which the flasks were placed in the humidified incubator. Cells in culture 
were monitored daily, and depending on the confluence of the cells observed in the flasks 
after microscopic examination and change in pH (orange coloration of medium), the old 
medium with puromycin was aspirated and replaced or the cells were passed. It is noteworthy 
that all manipulations of cells were performed in sterile Laminar flow hoods Microflow® 
Biosafety Cabinet Class II (Telstar) following established tissue culture standard operating 
procedures. 
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Table 2.1: Cell lines, origins, characteristics and suppliers. 
Cell line Origin and characteristics Producer 
MDA-MB-231 Human adenocarcinoma of the breast (derived from 
metastatic site: pleural effusion) 
ATCC® 
MDA-p36 KD-3 MDA-MB-231 cells expressing ANXA2 shRNA-3 
(obtained by cloning of the dsDNA oligo 5’-
GATCCCCCCTGGTTCAGTGCATTCAGTTCAAGA 
GACTGAATGCACTGAACCAGGTTTTTA-3’ and 5’-
AGCTTAAAAACCTGGTTCAGTGCATTCAGT 
CTCTTGAACTGAATGCACTGAACCAGGGGG-3’) in a 
pSUPER-retro-puro vector as “backbone” [OligoEngine]) 
Our 
Laboratory 
MDA-p36 KD-4 MDA-MB-231 cells expressing ANXA2 shRNA-4 
(obtained by cloning of the dsDNA oligo 5’-
GATCCCCGTGCATATGGGTCTGTCAATTCAAGAGA
TTGA CAGACCCATATGCACTTTTTA-3’ and 5’-
AGCTTAAAAAGTGCATATGGGTCTGTCAATCTCTTG
AATTGACAGACCCATATGCACGGG-3’ in a pSUPER-
retro-puro vector as “backbone” [OligoEngine]) 
Our 
Laboratory 
MDA-p36 
Scramble 
MDA-MB-231 cells expressing ANXA2 scramble (control) 
shRNA (obtained by clonining of the dsDNA oligo 5’-
GATCCCCGTGCATATGGGTCTGTCCATTAGAGAGA
TTGACAGACCCATATGCACTTTTTA-3’ and 5’-
AGCTTAAAAAGTGCATATGGGTCTGTCAATCTCTCT
AATGGACAGACCCATATGCACGGG-3’ in a pSUPER-
retro-puro vector as “backbone” [OligoEngine]) 
Our 
Laboratory 
293T  Human embryonic kidney epithelial cells ATCC® 
 
2.1.1. Passaging of cells, preparation of plates, treatments and stocks 
For passaging of cells, after examination under the microscope (Zeiss, primo vert), culture 
medium was aspirated, followed by washing of the cells with 5 ml (T75) or 2 ml (T25) of 
Dulbecco’s Phosphate Buffered Saline (without Ca2+ or Mg2+ - LONZA). The cells were then 
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detached by 3 – 5 minutes incubation with 3 ml (T75) or 1 ml (T25) of 0.25% trypsin-EDTA 
(SIGMA®) in a humidified atmosphere of 5% CO2 at 37º C. After observing complete 
detachment of the cells under the microscope for, 2.7 ml (T75) or 0.8 ml (T25) of the mixture 
was dispensed in to 15 ml tubes for further procedures, while the remaining volume was 
placed back in culture with fresh medium and 1 µg/ ml puromycin.  
The tubes were centrifuged at 1000g for 5 minutes and the resultant pellets re-suspended in 
4 ml of complete DMEM and homogenized. Cells were then counted by pipetting out 10 µL 
of the suspension and placing it into a 0.0025 mm2 Neubauer counting chamber (Hausser 
scientific) and counting the number of cells present in four squares of 1 mm2. The number of 
cells per ml were determined using the following formula:  
Average number of cells per square × dilution factor × 104 = number of cells per ml. 
In order to perform the signalling experiments with EGF stimulation, 60 mm sterile plates 
(VWR) were prepared, each with a final volume of 3 ml consisting of the cell suspension 
(usually about 5 x 105 cells/plate) and complete DMEM. The plates were incubated in a 
humidified atmosphere of 5% CO2 at 37º C for 24 to 48 hours, after which they were usually 
starved overnight (to minimize any serum-dependent and external effects) by taking out the 
complete DMEM, washing with phosphate buffered saline (PBS) and replacing it with 
DMEM without FBS. After checking the cells under the microscope and confirming 
equivalent confluency between the cell lines, the cells were treated with 50 ng/ml of EGF 
(biorbyt™ - orb49362) at various time points. 
Cell stocks were made for each of the cells used in this study, usually from the first selection 
after putting the cells in culture. In order to freeze the cells, the pellets (obtained as explained 
above) were re-suspended in a cryoprotective freezing solution (90 % FBS + 10 % DMSO), 
properly homogenized and pipetted into 2 ml freezing tubes (VWR and SIGMA®) with a cell 
density of 2-3 x 106 cells/ml. The freezing tubes were then wrapped in paper and rapidly 
stored in the -80°C deep freezer (New Brunswick Scientific) for 24 hours, after which they 
were transferred to -150 °C for long term storage. 
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2.2. Preparation of protein lysates and quantification 
In order to obtain the lysates containing all proteins from the cells, either not treated (NT) or 
after treatment with EGF for different time points (time courses), the medium from each 60 
mm plate was first discarded, followed by thorough washing with 1 ml of PBS (with Ca2+ 
and Mg2+) after which the PBS was pipetted out. 100 to 150 µL of lysis buffer (50 mM Tris-
HCL pH 7.5, 150 mM NaCl, 1 % Nonidet® P-40 substitute, 1 % sodium deoxycholate, 1 mM 
EDTA, 2 mM EGTA, 10 mM sodium fluoride (NaF), 1 mM sodium ortovanadate (Na3VO4), 
0.5 % protease inhibitors [SIGMA®, ref: P2714-1BTL]) was added to each plate followed by 
scrapping to lyse the cells. The resultant lysates were pipetted into priory labeled sterile 1.5 
ml Eppendorf tubes, left for 10 minutes on ice, and centrifuged at maximum speed (15000 g) 
in a refrigerated centrifuge (Heraeus™ Fresco 17 Centrifuge [Thermo-Scientific]) for 15 
minutes at 4 °C (precipitation of non-soluble components). After centrifugation, the 
supernatants were pipetted into fresh sterile Eppendorf tubes and stored at -80 °C. It is 
important to note that after treatments, all procedures were performed on ice (4 °C) to 
minimize protein degradation. 
Prior to running gels and western blots, the protein concentration in each sample was 
determined. The samples were prepared using the Pierce® bicinchoninic acid (BCA) protein 
assay kit (Thermo-scientific) according to the manufacturer’s instructions. The BCA protein 
assay is based on the reduction of Cu2+ to Cu+ by protein in an alkaline medium (Biuret 
reaction). This reduction permits the highly sensitive and selective colorimetric detection of 
the cuprous cation (Cu+) by BCA. The stoichiometric reaction involves the chelation of two 
molecules of BCA with each Cu+ forming a water soluble purple colored BCA/copper 
complex which exhibits a strong linear absorbance at 562 nm which is directly proportional 
to protein concentrations. Prior to each set of measurements, a linear calibration curve was 
established for a range of concentrations of interest (usually [0.4 – 1] µg/µl) using bovine 
serum albumin (BSA) standards provided as part of the kit. A reference solution containing 
milli Q water was also used for each set of measurements and the samples were diluted in a 
ratio of 1:10 in order to keep the concentrations within the calibration range. After proper 
blanking and calibration, the protein concentration in each sample was determined using the 
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NanoDrop 2000c UV-Vis Spectrophotometer (Thermo-Scientific) at 562 nm following the 
manufacturer’s guidelines. 
2.3. Western blotting  
For western blot analysis loading fractions containing 20 μg/20 μl of the extracted protein 
samples in 1x loading buffer (with or without β-mercaptoethanol), were subjected to SDS-
PAGE. The gels were prepared using the stock solutions of 40% de acrilamide:bisacrilamide 
(29:1) (AppliChem®), 1M Tris (pH 8,8), 10% SDS (AppliChem®), 25% ammonium 
persulfate (Sigma®), TEMED (AppliChem®) and milliQ water. Appart from the 
aforementioned constituents, the stacking gel was prepared using 1M Tris (pH 6,5) with a 
final concentration of 5% of acrilamide:bisacrilamide (29:1).Considering the expected sizes 
of the proteins of interest in this study, running gels with 10% and 12% of 
acrylamide:bisacrilamide (29:1) were used (details in appendix 4, page 75). The gels were 
run using the Mini-Protean (BioRad®) electrophoresis system and power source 
(PowerPac™ Basic power supply [BioRad®]) according to the manufacturer’s instructions, 
completely submerged in electrophoresis running buffer (details in appendix 5, page 76) with 
20 μl of sample (20 μg of protein) loaded into each well and 2 μl of the molecular weight 
marker (nzytech, batch-13121) in the first well. An initial voltage of 100 V (0.05 – 0.08 A) 
was used to get the proteins stacked into the running gel, after which the voltage was 
increased to 120 – 130 volts maintained at 0.05 – 0.08 A. The usual running time was about 
80 minutes. 
The separated proteins (in bands) within each gel were transferred on to 0.2 µm nitrocellulose 
membranes (BioTrace™ NT [Pall Corporation®]) using the standard sandwich transfer 
procedure 163, completely submerged in blotting buffer (details in annex) with ice packs, at 
100 V for 70 minutes. The membranes were then blocked with 5% skimmed milk in Tris 
buffered saline-tween 20 (TBS-T) for a minimum of 30 minutes (to prevent non-specific 
antibody binding, considering the high non-specific affinity of nitrocellulose membranes for 
proteins) at room temperature with mild shaking on the plate mixer (VWR® Mini Blot Mixer). 
After blocking, the membranes were incubated overnight at 4 °C (with mild shaking) with l 
primary antibody (in TBS-T with BSA or milk and 0.05% azide) specific for the target 
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proteins. After the first incubation, the membranes were washed four times each with 5 – 10 
ml of TBS-T (5 minutes per wash) with shaking after which they were incubated with 
appropriate horse radish peroxidase (HRP)-conjugated secondary antibodies (dilution of 1: 
5000 in TBS-T) for at least 1 hour and washed five times with 5 – 10 ml of TBS-T (5 minutes 
per wash) with shaking. All antibodies used in this study are indicated in table 2.2. The 
resultant protein bands were visualized using an enhanced chemiluminescence (ECL) 
solution (details in appendix 6, page 77) and images were obtained using a Molecular 
Imager® ChemiDoc™ XRS System (BioRad). 
Table 2.2: Primary and secondary antibodies used in this study 
Primary antibodies 
Antibody Description and reference Supplier 
p36 (annexin A2) Mouse IgG; Made in house 
p-AKT Rabbit IgG; sc-7985 Santa Cruz Biotechnology 
Total AKT Goat IgG; sc-1618 Santa Cruz Biotechnology 
p-ERK 1/2 Goat IgG; sc-16982 Santa Cruz Biotechnology 
Total ERK 1/2 Mouse IgG; sc-135900 Santa Cruz Biotechnology 
PTEN Mouse IgG; sc-7974 Santa Cruz Biotechnology 
PRDX II Goat IgG; sc-23967 Santa Cruz Biotechnology 
Actin Goat IgG; sc-1615 Santa Cruz Biotechnology 
Secondary antibodies 
Anti-mouse Donkey IgG-HRP; sc-2314 Santa Cruz Biotechnology 
Anti-goat Bovine IgG-HRP; sc-2384 Santa Cruz Biotechnology 
Anti-rabbit Goat IgG-HRP; sc-2004 Santa Cruz Biotechnology 
 
2.4. Biotinylated Iodoacetamide (BIAM) assay 
BIAM assays are widely used to asses modification (oxidation) of reactive Cys thiols based 
on the selective alkylation of free (non-oxidized) thiols and detection of alkylated proteins. 
Here, biotin conjugated iodoacetamide (BIAM) reacts with free reactive Cys thiolate anions 
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(reduced form) yielding biotin-carbamidomethylated cysteines, by bimolecular nucleophilic 
substitution (SN2) reactions and the biotin signal is subsequently measured by standard 
immunoblotting using streptavidin-conjugated-HRP 164,165. The loss or absence of the biotin 
signal is proportional to the degree of thiol oxidation 164.  
After treating the cells with EGF, lysis and protein extraction, 150 - 200 µL of each lysate 
was pipetted into fresh Eppendorf tubes containing 1 µL (200 µM) of BIAM, after which 
they were incubated for 30 minutes at room temperature, followed by 30 minutes incubation 
at 4 °C. The reaction was then stopped by adding 1 µL IAM (200 µM) after which the lysates 
were incubated for 15 minutes at 4 °C, centrifuged for 15 minutes at maximum speed (15000 
g) at 4 °C, and the supernatants were transferred into fresh Eppendorf tubes. 20 µg of each 
protein lysate was then analyzed by western blotting (see section 2.3) with HRP-conjugated 
streptavidin. 
2.5. Determination of intracellular ROS levels 
2′,7′ dichlorofluorescein diacetate (DCFH-DA) has been widely used as a potent marker for 
oxidative stress, and has been suggested to be a good indicator of the overall redox status of 
the cell 166. This hydrophobic non-fluorescent molecule performs its function by penetrating 
rapidly into the cell, where it is hydrolyzed by intracellular esterases to yield the DCFH 
molecule which can be oxidised (by ROS) to its fluorescent 2-electron product 
2′,7′dichlorofluorescein (DCF) that can be quantified by a fluorometer plate reader at Exc 
492 nm and Em 530 nm 166. Here, the amount of fluorescence observed is directly 
proportional to amount of ROS present in the cells. 
 
 For the ROS assays, 2 X 104 cells were set up in each well of a 96 wells plate, after which 
they were incubated in complete medium for 24 – 48 hours at 37 °C, 5% CO2. After 
microscopic examination of the wells, the medium was removed and the cells in each well 
were washed with 100 µl of PBS with Ca2+ after what the PBS was removed. Fresh PBS 
with Ca2+ containing 200 µM DCFH-DA reagent was then added (100 µl/ well) followed 
by incubation for 15-30 minutes at 37°C, 5% CO2 in the dark (DCF-DA is light sensitive) 
after which the cells were treated with EGF (50 ng/ml). Kinetic time course fluorescence 
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measurements were done using a fluorometer plate reader (TECAN – Infinite M200) at 
excitation - 492 nm and emission – 530 nm.  
2.6. Cell proliferation assay 
The evaluation of cell proliferation upon EGF stimulation in ANXA2 depleted and scramble 
cells was done using the CellTiter 96® non-radioactive Cell Proliferation Assay (Promega). 
This assay is based on the cellular mitochondrial reductase-catalyzed conversion of a 
tetrazolium salt (3-[4,5-dimethylthiazol-2-yI]-2,5-diphenyltetrazolium bromide), usually 
called MTT, into a formazan product ([E,Z]-5-[4,5-dimethylthiazol-2yI]-1,3-
diphenylformazan) that is easily detected by spectrophotometry using a 96-well plate reader 
167,168. Here, the 570 nm absorbance reading is directly proportional to the number of viable 
cells. 
For the MTT assays, 104 cells were set up in each well of a 96 wells plate and incubated in 
complete medium for 24 hours at 37°C, 5% CO2. After microscopic examination of the wells, 
the medium was removed and the cells in each well were washed with 100 µl of PBS after 
what the PBS was removed. The cells were then starved overnight by incubation at 37°C, 5% 
CO2, with DMEM without FBS and treated with EGF (50 ng/ml) for 6 – 24 hours. Five hours 
to the end of the required treatment time, 8 µL of the premixed optimized dye solution was 
added to each well, followed by 4 hour incubation at 37°C, 5% CO2 (for MTT conversion to 
formazan product). 40 µL of the solubilization solution/stop mix was then added to the wells 
to solubilize the formazan product (purple coloration observed) and the absorbance at 570 
nm was recorded using a 96-well plate reader (TECAN – Infinite M200).  
2.7. Statistical analysis 
The data obtained from the MTT (absorbance) and DCFH-DA (fluorescence) assays were 
transferred to spreadsheets (Microsoft excel 2013 ®) analyzed using the Student-t test for 
comparison of means at a 95 % confidence level. P-values below 0.05 were considered 
statistically significant. 
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3. RESULTS  
3.1. Analysis of activation of signalling pathways upon treatment
 with EGF 
In order to analyze the activation of signalling pathways in ANXA2 shRNA (knockdown) 
versus control (scramble shRNA) cancer cells upon treatment with EGF at different time 
points (time course), MDA-MB-231 cells (expressing ANXA2 shRNA or scramble shRNA) 
were cultured in 60 mm sterile plates and treated with 50 ng/ml of EGF (15 nM) at various 
time points followed by lysis to extract the protein content of these cells and western blot 
analysis with antibodies for a variety of target proteins (figures 3.1 and 3.2).  
 
Figure 3.1: ANXA2 knockdown cancer cells show enhanced activation of the PI3K 
signalling pathway in response to EGF treatment compared to control cells.  MDA-MB-231 cells 
(ANXA2 p36 shRNA 3 – left panel, ANXA2 p36 shRNA 4 – middle panel and ANXA2 p36 shRNA scramble – 
right panel) were treated with 50ng/ml EGF for the indicated times followed by western analysis with the above 
mentioned antibodies. 
The results obtained indicate that ANXA2 knockdown cells show enhanced activation of the 
PI3K signalling pathway in response to EGF treatment compared to control cells. This can 
be observed from the enhanced phosphorylation/activation of Akt (P-Akt) in the ANXA2 
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depleted cells as compared to the control cells upon EGF treatment. In order to further 
investigate and confirm the aforementioned observations, western blot analysis with 
antibodies for PTEN (the main inhibitor of the PI3K pathway), PRDX II (a redox regulatory 
protein) and the previously mentioned signalling proteins were done (figure 3.2). 
 
Figure 3.2: ANXA2 knockdown cancer cells show similar levels of PTEN and upregulation 
of PRDX II expression in response to EGF treatment compared to control cells. .  MDA-MB-
231 cells (ANXA2 p36 shRNA 3 – left panel, ANXA2 p36 shRNA 4 – middle panel and ANXA2 p36 shRNA 
scramble – right panel) were treated with 50ng/ml EGF for the indicated times followed by western blots with 
the above mentioned antibodies. 
The results in figure 3.2 indicate that ANXA2 knockdown and control MDA-MB-231 cells 
treated or not treated with EGF show identical levels of PTEN expression. Interestingly, 
ANXA2 knockdown seems to lead to the upregulation of the ROS scavenger protein, PRDX 
II in the MDA MB 231 cells. This might be to compensate for the loss of the ANXA2 redox 
regulatory protein. Considering the inhibitory phosphatase role of PTEN in the PI3K 
pathway, its inactivation is required for the activation of the pathway. In order to gain more 
insight into the activity of PTEN in MDA MB 231 cells upon EGF stimulation, a non-reduced 
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SDS-PAGE was done followed by western blot analysis with antibodies for PTEN and 
ANXA2 (figure 3.3). 
 
Figure 3.3: ANXA2 knockdown and control cells indicate a change in conformation of 
PTEN in response to EGF treatment. MDA-MB-231 cells (ANXA2 p36 shRNA 3 – left panel, ANXA2 
p36 shRNA 4 – middle panel and ANXA2 p36  shRNA scramble – right panel) were treated with 50ng/ml EGF 
for the indicated times followed by non-reduced SDS-PAGE and western blot analysis with the above mentioned 
antibodies. 293T cells with wild type and mutant (C–124-S) PTEN were also used as controls (last two lanes 
on the right).  
As explained earlier in this thesis, stimulation of cells with EGF leads to the production of 
ROS for downstream signalling. The results in figure 3.3 indicate the possibility of changes 
in conformation of PTEN upon EGF treatment which lowers the affinity of the monoclonal 
PTEN antibody used for this experiment as demonstrated by the significantly weaker signal 
upon EGF stimulation compared to non-treated cells. The presence of bands in the 293T cell 
panels shows that the antibody does not bind to the reactive Cys residue of PTEN (Cys124) 
44. It is therefore possible that the treatment of the cells with EGF leads to oxidation and 
conformational changes (disulfide bond formation) in PTEN which could inactivate it. The 
fact that under reducing conditions (figure 3.2.) the affinity of the PTEN antibody did not 
change if we compare the non-treated samples with the EGF treated samples, indicates that 
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the difference observed in non-reducing conditions is most likely due to conformational 
changes that occur via disulfide bond(s) formation upon EGF treatment. 
In summary, the above mentioned results indicate that ANXA2 knockdown cells show 
enhanced activation of the PI3K pathway and possible compensatory upregulation of PRDX 
II expression compared to control cells.  
3.2. Assessment of oxidation of reactive Cys residues in redox-
 sensitive proteins upon treatment with EGF 
BIAM assays were performed to assess the EGF induced ROS-mediated oxidation of reactive 
Cys residues in redox sensitive proteins in ANXA2 knockdown and control cells. Here, cell 
lysates were labeled with 200 µM of BIAM and subjected to SDS-PAGE and western blotting 
with a streptavidin probe (See section 2.4). A decrease in BIAM labeling of redox sensitive 
proteins, as observed by streptavidin blot analysis indicates oxidation of reactive Cys by the 
EGF induced ROS. The results obtained indicate that ANXA2 knockdown and control cells 
show similar redox profiles upon BIAM labelling after EGF treatment (figure 3.4). Overall 
there was no significant increase in total redox sensitive protein oxidation upon treatment 
with EGF. This is probably due to the nature of ROS dependent signaling which is mediated 
in the order of nanomolar concentrations of H2O2 (low concentration) and is very localized 
(within the area of signal transduction). For this reason the overall redox status of the cell 
does not seem to change significantly, as probably only a small fraction of redox sensitive 
proteins are being oxidized during EGF signaling. 
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Figure 3.4: ANXA2 knockdown and control cells show similar redox profiles upon BIAM 
labelling after EGF treatment under non-reduced conditions. MDA-MB-231 cells (ANXA2 p36 
shRNA 3 – left panel, ANXA2 p36 shRNA 4 – middle panel and ANXA2 p36 shRNA scramble – right panel) 
were treated with 50ng/ml EGF for the indicated times followed by labelling with 200 µM of BIAM, SDS-PAGE 
and western blot analysis with  streptavidin probe. 
3.3. Analysis of ROS levels in ANXA2 knockdown versus control 
 MDA-MB-231 cancer cells upon treatment with EGF 
In order to investigate if ANXA2 plays a role in ROS inactivation upon EGF treatment, the 
ROS levels of ANXA2 knockdown versus control cancer cells were analyzed. Here, the 
intracellular ROS levels in non-treated cells and cells treated with 50 ng/ml of EGF for 15 
minutes were measured using the fluorescent probe, 2′,7′ dichlorofluorescein diacetate 
(DCFH-DA)[see section 2.5]. As expected, treatment of MDA MB 231 cells with EGF led 
to enhanced levels of ROS in the ANXA2 depleted and control cells (figure 3.5). These 
results also showed that ROS levels were significantly higher in ANXA2 knockdown cells 
compared to control cells after treatment with EGF for 15 minutes indicating that ANXA2 
plays a role in ROS inactivation upon EGF induced signalling (figure 3.5). Comparison of 
the levels of ROS between the ANXA2 depleted and control cells revealed a significant 
increase in ROS levels in ANXA2 p36 knockdown-3 cells (P = 0.000042) and ANXA2 p36 
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knockdown-4 cells (P = 0.042) compared to control cells confirming the aforesaid 
observation. 
 
Figure 3.5: ANXA2 knockdown cells accumulate higher levels of ROS upon EGF 
stimulation. MDA-MB-231 cells (ANXA2 p36 shRNA 3 – blue, ANXA2 p36 shRNA 4 – orange and ANXA2 
p36 shRNA scramble – grey) were serum starved for 16 hours and then incubated with 200 µM of DCFH-DA 
reagent, followed by treatment with 50 ng/ml EGF for 15 minutes. Fluorescence was measured using a 
fluorometer plate reader (Exc. 492 nm, Em. 524 nm). Data are represented as fold induction of ROS between 
non-treated and treated cells (N = 6). P-values represent the difference in ROS levels between non-treated and 
EGF treated cells at 95 % significance level. 
3.4. Evaluation of the role of ANXA2 in cell proliferation induced 
 by the EGF/EGFR signalling pathways 
In order to analyse if ANXA2 is important for cell proliferation induced by the EGF/EGFR 
signalling pathways, the rate of proliferation of ANXA2 depleted and scramble (control) 
MDA MB 231 cells was measured using the CellTiter 96® non-radioactive Cell Proliferation 
MTT Assay (see section 2.6). Here the rate of proliferation of ANXA2 depleted and control 
cells was determined upon treatment with 50 ng/ml of EGF for 24 hours and compared with 
proliferation rates in non-treated cells (figure 3.6). A comparison of the proliferation rates 
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between the non-treated and EGF-treated ANXA2 depleted cells indicated a significant 
increase in the rate of proliferation upon EGF treatment (P-values shown on figure 3.6), while 
the control cells showed a non-significant increase in proliferation rate upon treatment with 
EGF (P = 0.40). A comparison of the rate of proliferation between the ANXA2 depleted and 
control cells revealed a significant increase in the proliferation rate of ANXA2 p36 
knockdown-3 cells (P = 0.020) and ANXA2 p36 knockdown-4 cells (P = 0.0017) compared 
to control cells. These results show that ANXA2 knockdown cells have higher rates of 
proliferation upon EGF treatment compared to control cells. 
 
Figure 3.6: ANXA2 knockdown cells have a higher proliferative rate upon EGF treatment 
compared to control cells. MDA-MB-231 cells (ANXA2 shRNA 3 – blue, ANXA2 shRNA 4 – orange and 
ANXA2 shRNA scramble – grey) were serum starved for 16 hours followed by mock treatment or treatment with 
50 ng/ml EGF for 24 hours. Absorbance (λ = 570 nm) was measured after a tetrazolium reduction cell 
proliferation assay. Data are represented as folds of increase in proliferation rates between mock treated and 
treated cells (N = 6). P-values represent the difference in ROS levels between non-treated and EGF treated 
cells at 95 % significance level. 
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4. Discussion 
Our laboratory recently identified ANXA2 as a new redox regulatory protein in cells that 
plays a major role during oxidative stress and particularly in tumorigenesis 116. As a follow 
up to this research, the present study aimed at investigating the role of ANXA2 in GF/GFR 
induced ROS mediated signalling. The choice of EGF/EGFR is as a result of the fact that the 
binding of EGF to its cell surface receptor leads to downstream evens that transiently increase 
the intracellular levels of H2O2 for downstream signalling events (activation of kinases and 
deactivation of phosphatases) 35,103. 
As stated earlier in this thesis, the PI3K pathway plays a key ROS-dependent role in cell 
proliferation and survival in response to EGF stimulation and is one of the most mutated 
pathways in cancer 42,68. The results of this work show, for the first time, that ANXA2 
knockdown in cancer cells leads to enhanced activation of the PI3K pathway (figure 3.1) in 
response to EGF treatment. This study also showed that ANXA2 depleted cells have higher 
levels of ROS and proliferation rates upon treatment with EGF. Together these results 
suggest that the stimulation of ANXA2 depleted cancer cells with EGF leads to enhanced 
H2O2 levels that over activate PI3K signalling compared to control cells. As a result of this, 
the ANXA2 depleted cells show higher proliferative rates in response to EGF treatment. 
ANXA2 therefore plays a redox regulatory role via modulation of the PI3K pathway. The 
phosphatase, PTEN, is the main inhibitor of the PI3K pathway and contains reactive Cys 
residues in its catalytic domain that can be readily oxidized by H2O2 inactivating its 
phosphatase function 104. The inactivation of PTEN is a pre-requisite for PI3K signalling. 
Our results show that the treatment of ANXA2 knockdown and control cells with EGF does 
not significantly alter the expression of PTEN (figure 3.2). This demonstrates that the 
inactivation of PTEN upon EGF treatment is not as a result of a decrease in expression, but 
most probably due to the EGF induced ROS mediated oxidation of the reactive Cys residues 
in its catalytic site. These results are in agreement with earlier studies which demonstrate a 
reversible inactivation of PTEN by H2O2 as a regulatory mechanism for PI3K signalling 
43,103,104. Further in vitro and in vivo experiments with different cancer cell types are ongoing 
in our laboratory to confirm the aforementioned results. 
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The results obtained with western blots for PTEN upon treatment of the cells with EGF under 
non-reduced conditions indicate the possibility of changes in conformation of PTEN upon 
EGF treatment which lowers the affinity of the monoclonal PTEN antibody used for this 
experiment (figure 3.3). This result, coupled to the fact that in reducing conditions the affinity 
of the PTEN antibody did not change in the non-treated samples compared to EGF treated 
samples (figure 3.2.) indicates that the difference observed in non-reducing conditions is 
most likely due to conformational changes that occur via disulfide bond(s) formation upon 
EGF treatment. Therefore the treatment of the cells with EGF leads to an increase in 
intracellular ROS levels (more so in ANXA2 depleted cells) which may lead to oxidation 
and conformational changes in PTEN which could inactivate it and by so doing, enhance the 
ROS mediated activation of PI3K signalling. However, western blot analysis is required with 
monoclonal antibodies specific for the catalytic site reactive Cys residues of PTEN to validate 
these assertions. Further research is ongoing in our laboratory to determine the interactions 
between ANXA2 and PTEN in a bid to better understand the redox regulatory functions of 
ANXA2. 
PRDX II is a highly abundant antioxidant protein present in the cytosol of several cell types 
24. In order to investigate the role of PRDX II in EGF induced signalling in ANXA2 depleted 
and control cells, western blotting with an antibody for PRDX II was done (figure 3.2). 
Interestingly, the results obtained demonstrate, for the first time, that MDA MB 231 ANXA2 
knockdown cells show higher levels of PRDX II compared to control cancer cells. This result 
suggests that the cells might be responding to ANXA2 knockdown by increasing the 
expression of another ROS scavenger, PRDX II to compensate for the loss of ANXA2 redox 
regulatory function. Further investigation of the possible cross talk between ANXA2 and 
PRDX II is currently ongoing in our laboratory. 
Investigation of the role of ANXA2 in the pro-proliferative ERK pathway revealed enhanced 
activation of ERK (P-ERK) in MDA MB 231 ANXA2 shRNA-3 but not in the MDA MB 
231 ANXA2 shRNA-4 and control cells (figures 3.1 and 3.2). These results were not 
conclusive since the activation was not observed in MDA MB 231 ANXA2 shRNA-4 cells 
which portray a better knockdown of ANXA2. Further optimization and analysis is necessary 
for future exploration of this pathway. 
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Assessment of oxidation of reactive Cys residues in redox sensitive proteins by BIAM 
labelling upon treatment with EGF indicate that ANXA2 knockdown and control cells show 
similar redox profiles after EGF treatment (figure 3.4). Treatment of the cells with 50 ng/ml 
of EGF for the times indicated may just lead to differential mild and localized physiological 
increases in intracellular ROS levels in the MDA MB 231 ANXA2 knockdown and control 
cells. In addition, the EGF concentrations used in this study are not high enough to induce 
supraoptimal ROS levels and the cells were not exposed to exogenous sources of ROS.  
Analysis of ROS levels in ANXA2 knockdown versus control MDA-MB-231 cancer cells 
upon treatment with EGF revealed that ROS levels were significantly higher in ANXA2 
knockdown cells compared to control cells after treatment with EGF for 15 minutes (figure 
3.5). This implies that ANXA2 plays a role in ROS inactivation upon EGF induced 
signalling. Therefore, treatment of ANXA2 knockdown MDA-MB-231 cancer cells with 
EGF leads to an intracellular increase and accumulation of ROS, an effect which is 
significantly less observed in control cells.  This result is in agreement with the results 
obtained by Madureira et al., in a study which showed that ANXA2 depleted cells accumulate 
higher concentrations of ROS upon treatment with various concentrations of H2O2 in TIME, 
LCC and MCF7 cancer cells 116. ANXA2 depleted cells accumulate more H2O2 upon 
treatment with EGF compared to control cells, which leads to enhanced activation of the ROS 
dependent PI3K pathway as observed in the results of the signalling experiments. 
Evaluation of the role of ANXA2 in cell proliferation induced by the EGF/EGFR signalling 
pathways revealed that ANXA2 knockdown cells have higher rates of proliferation upon 
EGF treatment compared to control cells (figure 3.6). These results are in line with the 
aforementioned observations of enhanced activation of the pro-proliferative ROS dependent 
PI3K pathway in ANXA2 knockdown cells which accumulate more ROS and proliferate at 
a higher rate compared to control cells upon EGF treatment. Since ANXA2 depleted cells 
reveal significantly higher levels of ROS as compared to control cells upon treatment with 
EGF, the ROS so produced could be responsible for the enhanced activation of the PI3K 
pathway, inhibition of PTEN and increased rate of proliferation observed in the ANXA2 
depleted cells compared to control cells. Also, ANXA2 knockdown seems to lead to the 
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upregulation of PRDX II.  Additional research is ongoing in our laboratory to further 
elaborate/develop and confirm these findings. 
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5. Conclusions and future perspectives 
5.1. Conclusions  
Several studies have demonstrated the upregulation of ANXA2 in various types of cancer 
whereby it has been positively linked with cancer progression, resistance to chemotherapy 
and radiotherapy, and poor prognosis. However, the function(s) and mechanism of action of 
ANXA2 in cancer have not been fully described. EGF is a potent inducer of intracellular 
ROS production for second messenger signalling in normal and cancer cells. The recent 
elucidation of a redox regulatory function for ANXA2 by our laboratory led us to investigate 
the role(s) of ANXA2 in EGF induced signalling in cancer cells. The results of this study 
show that ANXA2 depletion in MDA MB 231 cancer cells leads to enhanced activation of 
the pro-proliferative PI3K pathway, upregulation of PRDX II, enhanced ROS production and 
increased rates of proliferation upon EGF treatment compared to control cells. Our results 
provide more insights into the redox regulatory functions of ANXA2 and help to better 
understand the ROS dependent mechanisms of cancer development in a bid to provide novel 
anticancer strategies. Our results demonstrate that ANXA2 plays a redox regulatory role in 
EGF induced ROS-mediated PI3K/Akt signalling and ANXA2 knockdown cells might be 
upregulating PRDX II to compensate for the loss of the ANXA2 redox regulatory protein. 
Additional research work is ongoing to validate and further develop these results.  
The results of this work are part of a manuscript in preparation: Castaldo SA, Ajime T, 
Madureira PA. “Annexin A2 inhibits the PI3K/Akt pathway in cancer cells via the REDOX 
regulation of PTEN”. EMBO. IF: 10.748. My work was also presented in poster format at 
the special EACR/AACR/SIC conference on anticancer drug action and drug resistance: 
from cancer biology to the clinic held in Florence, Italy, (20th - 23rd June, 2015) [appendix 1, 
page 72] and at the oncobiology retreat organised by the CBMR/UAlg on the 20th May 2015 
(appendix 3, page 74). 
5.2. Future perspectives 
In order to validate the above mentioned findings, we will be carrying out the above 
mentioned procedures in different cancer cell types and with other growth factors (such as 
platelet derived growth factor [PDGF]) in vitro and in vivo. Co-immunoprecipitation (Co-IP) 
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assays will be done to further investigate the interactions between ANXA2 and PTEN in a 
bid to propose a plausible redox regulatory mechanism for ANXA2 in PI3K signalling. 
To further investigate and validate the compensatory upregulation of PRDX II in ANXA2 
depleted cells, various cancer cell lines will be established with shRNA mediated knockdown 
for ANXA2, PRDX II and both. The activation of various signalling pathways upon treatment 
with H2O2, EGF or ROS inducing therapeutics will be investigated to evaluate the 
physiological outcomes of the knockdowns. Co-IPs will also be done to investigate if 
ANXA2 and PRDX II might interact or bind to similar target proteins. 
Considering the nuclear functions of ANXA2 and the existence of redox regulated 
transcription factors, we could also investigate the role of ANXA2 in the regulation of the 
activity of redox sensitive transcription factors. 
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Appendix 1: Poster presented at the special EACR/AACR/SIC conference, Florence, Italy, 
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Appendix 4: Composition of running and stacking gels for SDS-PAGE 
Running gels Stacking gel 
(acrylamide:bisacrilamide) % 10% 12% (acrylamide:bisacrilamide) % 5% 
1M Tris pH 8.8 3 ml 3 ml 1M Tris pH 6.5 
312.5 µl 
40 % 
acrylamide:bisacrylamide 2 ml 2.4 ml 
40 % 
acrylamide:bisacrylamide 312.5 µl 
Distilled H2O 2.9 ml 2.5 ml Distilled H2O 2.6 ml 
10 % SDS 80 µl 80 µl 10 % SDS 25 µl 
25 % APS 32 µl 32 µl 25 % APS 12.5 µl 
TEMED 12 µl 12 µl TEMED 7.5 µl 
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Appendix 5: Buffers for SDS-PAGE 
10 X running buffer stock 
- 250 mM Tris base 
- 2.5 M glycine 
- 1 % SDS 
(Gels were run using 1 X running buffer.) 
10 X Transfer Buffer stock (without methanol) 
- 250 mM Tris base 
- 2 M glycine 
(Transfers were done using 1 X transfer buffer with 20% of methanol per unit volume.) 
4 X protein loading buffer 
- 8 % SDS 
- 120 mM Tris pH 6.8 
- 20 % glycerol 
- 0.02 % bromophenol blue 
- 20 % β-mercaptoethanol 
20 X TBS buffer 
- 400 mM Tris pH7.5 
- 2.4 M NaCl 
(Working solutions of 1 X TBS-T (1 X TBS + 0.1% tween 20) were used to wash 
nitrocellulose membranes.) 
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Appendix 6: Composition of the enhanced chemiluminescence (ECL) solution 
Solution 1: 
- 20 ml 1 M Tris, pH 8.5 (100 mM Tris pH 8.5) 
- 2 ml luminol (2.5 mM luminol) 
- 889 l p-coumaric acid (360 uM p-coumaric acid) 
- 178 ml H2O 
Solution 2: 
- 20 ml 1 M Tris, pH 8.5 (100 mM Tris pH 8.5) 
- 180 ml H2O 
- 123 l 30% H2O2 (0.0185 % H2O2) 
(Working solutions of the ECL were prepared as 1 : 1 mix of solutions 1 and 2 in the 
absence of light.) 
stock solutions: 
- 250 mM luminol (3-aminophtalhydrazid) in DMSO 
- 90 mM p-coumaric acid in DMSO 
- keep solutions at 4ºC 
Chemicals: 
- p-Coumaric acid - Sigma C-9008 
- 5-Amino-2,3-dihydro-1,4-phthalazidedione (3-aminophtalhydrazid) = Luminol - 
Sigma A-8511 
- Hydrogen peroxide - Sigma H-1009 
 
